WO2001048004A1 - A new polypeptide-heparin bind protein 10 and the polynucleotide encoding it - Google Patents

A new polypeptide-heparin bind protein 10 and the polynucleotide encoding it Download PDF

Info

Publication number
WO2001048004A1
WO2001048004A1 PCT/CN2000/000704 CN0000704W WO0148004A1 WO 2001048004 A1 WO2001048004 A1 WO 2001048004A1 CN 0000704 W CN0000704 W CN 0000704W WO 0148004 A1 WO0148004 A1 WO 0148004A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
polynucleotide
heparin
binding protein
sequence
Prior art date
Application number
PCT/CN2000/000704
Other languages
French (fr)
Chinese (zh)
Inventor
Yumin Mao
Yi Xie
Original Assignee
Shanghai Biowindow Gene Development Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biowindow Gene Development Inc. filed Critical Shanghai Biowindow Gene Development Inc.
Priority to AU21459/01A priority Critical patent/AU2145901A/en
Publication of WO2001048004A1 publication Critical patent/WO2001048004A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723Cationic antimicrobial peptides, e.g. defensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Definitions

  • the present invention belongs to the field of biotechnology. Specifically, the present invention describes a novel polypeptide, heparin binding protein 10, and a polynucleotide sequence encoding the polypeptide. The invention also relates to the preparation method and application of the polynucleotide and polypeptide.
  • Sequence fragment 2 C- [R]-[LIVM] -P-C-N-W-K-K-X-F-G-A- [DE] -C- -Y-X-F- [EQ]-X-W-G-X-C;
  • Both of these sequence fragments contain a large number of cysteine residues and are present in all family members.
  • This sequence fragment may be an important active region where the protein binds to other proteins and exerts its growth regulating function. Mutations of these two fragments will affect the protein's normal physiological function in vivo. Members of this protein family are involved in important regulatory processes of cell differentiation and growth in the body, and abnormal expression of such proteins will cause some of the organism's related metabolic pathways to be abnormal. The abnormal expression of this protein is usually related to the occurrence of various developmental metabolic disorders, some tumors and cancers in the body.
  • Another object of the invention is to provide a polynucleotide encoding the polypeptide.
  • Another object of the present invention is to provide a recombinant vector containing a polynucleotide encoding a heparin-binding protein 10.
  • Another object of the present invention is to provide a genetically engineered host cell containing a polynucleotide encoding a heparin-binding protein 10.
  • Another object of the present invention is to provide a method for producing heparin-binding protein 10.
  • Another object of the present invention is to provide a method for diagnosing and treating diseases related to abnormalities in heparin binding protein 10.
  • the present invention relates to an isolated polypeptide, which is of human origin and comprises: a polypeptide having the amino acid sequence of SEQ ID No. 2, or a conservative variant, biologically active fragment or derivative thereof.
  • the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: 2.
  • the invention also relates to an isolated polynucleotide comprising a nucleotide sequence or a variant thereof selected from the group consisting of:
  • sequence of the polynucleotide is one selected from the group consisting of: (a) a sequence having positions 343-618 in SEQ ID NO: 1; and (b) a sequence having 1-1865 in SEQ ID NO: 1 Sequence of bits.
  • the invention further relates to a vector, in particular an expression vector, containing a polynucleotide of the invention.
  • the vector genetically engineered host cell includes a transformed, transduced or transfected host cell; a method for preparing a polypeptide of the present invention comprising culturing the host cell and recovering an expression product.
  • the invention also relates to an antibody capable of specifically binding to a polypeptide of the invention.
  • the present invention also relates to a method for screening compounds that mimic, activate, antagonize or inhibit the activity of heparin-binding protein 100, which comprises utilizing the polypeptide of the present invention.
  • the invention also relates to compounds obtained by this method.
  • the invention also relates to a method for in vitro detection of a disease or susceptibility to disease associated with abnormal expression of a heparin-binding protein 10 protein, comprising detecting a mutation in the polypeptide or a sequence encoding a polynucleotide thereof in a biological sample, or detecting a biological sample.
  • the amount or biological activity of a polypeptide of the invention comprising detecting a mutation in the polypeptide or a sequence encoding a polynucleotide thereof in a biological sample, or detecting a biological sample.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a polypeptide of the invention or a mimetic thereof, an activator, an antagonist or an inhibitor, and a pharmaceutically acceptable carrier.
  • Fig. 1 is a comparison diagram of the amino acid sequence homology of a total of 71 amino acids of heparin-binding protein 10 of the present invention and characteristic domains of heparin-binding protein.
  • the upper sequence is heparin-binding protein 10
  • the lower sequence is the characteristic domain of heparin-binding protein.
  • ⁇ "and”: “and”. “Indicate that the probability of the same amino acid decreasing between the two sequences decreases in order.
  • Figure 2 shows the polyacrylamide gel electrophoresis (SDS-PAGE) of the isolated heparin-binding protein 10.
  • Kkda is the molecular weight of the protein.
  • the arrow indicates the isolated protein band.
  • Nucleic acid sequence refers to an oligonucleotide, a nucleotide or a polynucleotide and a fragment or part thereof, and may also refer to a genomic or synthetic DNA or RNA, they can be single-stranded or double-stranded, representing the sense or antisense strand.
  • amino acid sequence refers to an oligopeptide, peptide, polypeptide or protein sequence and fragments or portions thereof.
  • Insertion means that a change in the amino acid sequence or nucleotide sequence results in an increase in one or more amino acids or nucleotides compared to a molecule that exists in nature.
  • Replacement refers to the replacement of one or more amino acids or nucleotides with different amino acids or nucleotides.
  • An "agonist” refers to a molecule that, when bound to a heparin-binding protein 10, causes the protein to change, thereby regulating the activity of the protein.
  • An agonist may include a protein, a nucleic acid, a carbohydrate, or any other molecule that can bind heparin binding protein 10.
  • Antagonist refers to a molecule that can block or regulate the biological or immunological activity of heparin-binding protein 10 when bound to heparin-binding protein 10.
  • Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecule that can bind heparin-binding protein 10.
  • Regular refers to a change in the function of heparin-binding protein 10, including an increase or decrease in protein activity, a change in binding characteristics, and any other biological, functional, or immune properties of heparin-binding protein 10.
  • Substantially pure ' means essentially free of other proteins, lipids, sugars or other substances with which it is naturally associated.
  • Those skilled in the art can purify heparin-binding protein 10 using standard protein purification techniques. Basically pure The heparin binding protein 10 can generate a single main band on a non-reducing polyacrylamide gel. The purity of the heparin binding protein 10 polypeptide can be analyzed by amino acid sequence.
  • Complementary refers to the natural binding of polynucleotides by base-pairing under conditions of acceptable salt concentration and temperature.
  • sequence C-T-G-A
  • complementary sequence G-A-C-T
  • the complementarity between two single-stranded molecules can be partial or complete.
  • the degree of complementarity between nucleic acid strands has a significant effect on the efficiency and strength of hybridization between nucleic acid strands.
  • “Homology” refers to the degree of complementarity and can be partially homologous or completely homologous.
  • Partial homology refers to a partially complementary sequence that at least partially inhibits hybridization of a fully complementary sequence to a target nucleic acid. This Inhibition of hybridization can be detected by performing hybridization (Southern blotting or Nor thern blotting, etc.) under conditions of reduced stringency. Substantially homologous sequences or hybridization probes can compete and inhibit the binding of completely homologous sequences to the target sequence under conditions of reduced stringency. This does not mean that the conditions of reduced stringency allow non-specific binding, because the conditions of reduced stringency require that the two sequences bind to each other as a specific or selective interaction.
  • the percent identity between nucleic acid sequences can also be determined by the Clus ter method or by methods known in the art such as Jotun Hein (Hein J., (1990) Methods in enzymo logy 183: 625-645).
  • Antisense refers to a nucleotide sequence that is complementary to a particular DNA or RNA sequence.
  • the "antisense strand” refers to a nucleic acid strand that is complementary to the “sense strand”.
  • Derivative refers to HFP or a chemical modification of its nucleic acid. Such a chemical modification may be a substitution of a hydrogen atom with a fluorenyl group, an acyl group or an amino group. Nucleic acid derivatives can encode polypeptides that retain the main biological properties of natural molecules.
  • Antibody refers to a complete antibody molecule and its fragments, such as Fa,? ( ⁇ ') 2 and? It can specifically bind to the epitope of heparin-binding protein 10.
  • a “humanized antibody” refers to an antibody in which the amino acid sequence of a non-antigen binding region is replaced to become more similar to a human antibody, but still retains the original binding activity.
  • isolated refers to the removal of a substance from its original environment (for example, its natural environment if it occurs naturally).
  • a naturally-occurring polynucleotide or polypeptide exists in a living animal. It is not isolated, but the same polynucleotide or polypeptide is separated from some or all of the substances that coexist with it in the natural system.
  • Such a polynucleotide may be part of a certain vector, or such a polynucleotide or polypeptide may be part of a certain composition. Since the carrier or composition is not a component of its natural environment, they are still isolated.
  • isolated refers to the separation of a substance from its original environment (if it is a natural substance, the original environment is the natural environment).
  • polynucleotides and polypeptides in a natural state in a living cell are not isolated and purified, but the same polynucleotides or polypeptides are separated and purified if they are separated from other substances existing in the natural state. .
  • isolated heparin binding protein 10 means that heparin binding protein 10 is substantially free of other proteins, lipids, carbohydrates or other substances with which it is naturally associated. Those skilled in the art can purify heparin binding protein 10 using standard protein purification techniques. Substantially pure polypeptides can produce a single main band on a non-reducing polyacrylamide gel. The purity of the heparin-binding protein 10 peptide can be analyzed by amino acid sequence.
  • the present invention provides a new polypeptide, heparin-binding protein 10, which basically consists of the amino acid sequence shown in SEQ ID NO: 2.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide, and preferably a recombinant polypeptide.
  • the polypeptides of the present invention can be naturally purified products or chemically synthesized products, or can be produced from prokaryotic or eukaryotic hosts (eg, bacteria, yeast, higher plants, insects, and mammalian cells) using recombinant techniques. Depending on the host used in the recombinant production protocol, the polypeptide of the invention may be glycosylated, or it may be non-glycosylated. Polypeptides of the invention may also include or exclude starting methionine residues.
  • the invention also includes fragments, derivatives and analogs of heparin-binding protein 10.
  • fragment refers to a polypeptide that substantially maintains the same biological function or activity of the heparin-binding protein 10 of the present invention.
  • the fragment, derivative or analog of the polypeptide of the present invention may be: (I) a kind in which one or more amino acid residues are replaced with conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the substitution
  • the amino acid may or may not be encoded by a genetic codon; or (II) a type in which a group on one or more amino acid residues is substituted by another group to include a substituent; or ( ⁇ ⁇ )
  • Such a type in which the mature polypeptide is fused with another compound such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol
  • UV a type in which the additional amino acid sequence is fused into the mature polypeptide and formed by the polypeptide sequence ( Such as a leader sequence or a secreted sequence or a sequence used to purify this polypeptide or a protein sequence).
  • such fragments, derivatives and analogs are considered to be within the knowledge of those skilled in the art.
  • the polynucleotide of the present invention may be in the form of DM or RNA.
  • DNA forms include cDNA, genomic DNA or synthetic DNA.
  • DNA can be single-stranded or double-stranded.
  • DNA can be coding or non-coding.
  • the coding region sequence encoding a mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant.
  • a "degenerate variant" refers to a nucleic acid sequence encoding a protein or polypeptide having SEQ ID NO: 2 but different from the coding region sequence shown in SEQ ID NO: 1 in the present invention.
  • the invention also relates to variants of the polynucleotides described above, which encode polypeptides or fragments, analogs and derivatives of polypeptides having the same amino acid sequence as the invention.
  • This polynucleotide variant can be a naturally occurring allelic variant or a non-naturally occurring variant.
  • These nucleotide variants include substitution variants, deletion variants, and insertion variants.
  • an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .
  • the invention also relates to a polynucleotide that hybridizes to the sequence described above (having at least 50%, preferably 70% identity between the two sequences).
  • the present invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the present invention under stringent conditions.
  • “strict conditions” means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1% SDS, 6 (TC; or (2) Add denaturants during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Fico ll, 42 ° C, etc .; or (3) only between the two sequences Hybridization occurs only when the identity is at least 95%, and more preferably 97%. Furthermore, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO: 2.
  • nucleic acid fragments that hybridize to the sequences described above.
  • a "nucleic acid fragment” contains at least 10 nucleotides in length, preferably at least 20-30 nucleotides, more preferably at least 50-60 nucleotides, and most preferably at least 100 nuclei. Glycylic acid or more. Nucleic acid fragments can also be used in nucleic acid amplification techniques, such as PCR, to identify and / or isolate polynucleotides encoding heparin-binding protein 10.
  • the polypeptides and polynucleotides in the present invention are preferably provided in an isolated form and are more preferably purified to homogeneity.
  • polynucleotide sequence encoding the heparin-binding protein 10 of the present invention can be obtained by various methods.
  • polynucleotides are isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect homologous polynucleotide sequences, and 2 ) antibody screening of expression libraries to detect cloned polynucleosides with common structural characteristics Acid fragments.
  • the DNA fragment sequence of the present invention can also be obtained by the following methods: 1) isolating the double-stranded DNA sequence from the genomic DNA; 2) chemically synthesizing the DNA sequence to obtain the double-stranded DM of the polypeptide.
  • genomic DNA isolation is the least commonly used. Direct chemical synthesis of DM sequences is often the method of choice.
  • the more commonly used method is the isolation of cDNA sequences.
  • the standard method for isolating the cDNA of interest is to isolate mRNA from donor cells that overexpress the gene and perform reverse transcription to form a plasmid or phage cDNA library.
  • Various methods have been used to extract mRNA, and kits are also commercially available (Qiagene).
  • the construction of cDNA libraries is also a common method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989).
  • Commercially available cDNA libraries are also available, such as different cDNA libraries from Clontech. When polymerase reaction technology is used in combination, even very small expression products can be cloned.
  • genes of the present invention can be selected from these cDNA libraries by conventional methods. These methods include (but are not limited to): (1) DM-DNA or DNA-RNA hybridization; (2) the presence or absence of marker gene functions; (3) measuring the level of transcripts of heparin-binding protein 10; (4) passing Immunological techniques or assays for biological activity to detect gene-expressed protein products. The above methods can be used singly or in combination.
  • the probe used for hybridization is homologous to any part of the polynucleotide of the present invention, and its length is at least 10 nucleotides, preferably at least 30 nucleotides, more preferably At least 50 nucleotides, preferably at least 100 nucleotides.
  • the length of the probe is usually within 2000 nucleotides, preferably within 1000 nucleotides.
  • the probe used here is usually a DNA sequence chemically synthesized based on the gene sequence information of the present invention.
  • the genes or fragments of the present invention can of course be used as probes.
  • DNA probes can be labeled with radioisotopes, luciferin, or enzymes (such as alkaline phosphatase).
  • immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA) can be used to detect the protein product expressed by the heparin-binding protein 10 gene expression.
  • ELISA enzyme-linked immunosorbent assay
  • a method of amplifying DNA / RNA by PCR is preferably used to obtain the gene of the present invention.
  • the RACE method RACE-rapid cDNA end rapid amplification method
  • the primers for PCR can be appropriately based on the polynucleotide sequence information of the present invention disclosed herein Select and synthesize using conventional methods.
  • the amplified DNA / RNA fragments can be isolated and purified by conventional methods such as by gel electrophoresis.
  • the present invention also relates to a vector comprising a polynucleotide of the present invention, and a host cell genetically engineered using the vector of the present invention or directly using a heparin-binding protein 10 coding sequence, and a method for producing a polypeptide of the present invention by recombinant technology.
  • a polynucleotide sequence encoding a heparin-binding protein 10 may be inserted into a vector to form a recombinant vector containing the polynucleotide of the present invention.
  • vector refers to bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors well known in the art.
  • Vectors suitable for use in the present invention include, but are not limited to: T7 promoter-based expression vectors expressed in bacteria (Rosenberg, et al.
  • any plasmid and vector can be used to construct a recombinant expression vector.
  • An important feature of expression vectors is that they usually contain origins of replication, promoters, marker genes, and translational regulatory elements.
  • DNA sequence can be operably linked to an appropriate promoter in an expression vector to guide the synthesis of raRNA.
  • promoters are: the lac or trp promoter of E.
  • the expression vector also includes a ribosome binding site and a transcription terminator for translation initiation. Insertion of enhancer sequences into the vector will enhance its transcription in higher eukaryotic cells. Enhancers are cis-acting factors expressed by DM, usually about 10 to 300 base pairs, which act on promoters to enhance gene transcription. Illustrative examples include SV40 enhancers from 100 to 270 base pairs on the late side of the origin of replication, polyoma enhancers on the late side of the origin of replication, and adenovirus enhancers.
  • the expression vector preferably contains one or more selectable marker genes to provide for selection
  • selectable marker genes to provide for selection
  • the phenotypic traits of transformed host cells such as dihydrofolate reductase, neomycin resistance and green fluorescent protein (GFP) for eukaryotic cell culture, or tetracycline or ampicillin resistance for E. coli.
  • GFP green fluorescent protein
  • a polynucleotide encoding a heparin-binding protein 10 or a recombinant vector containing the polynucleotide can be transformed or transduced into a host cell to constitute a genetically engineered host cell containing the polynucleotide or the recombinant vector.
  • the term "host cell” refers to a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples are: E.
  • coli Streptomyces
  • bacterial cells such as Salmonella typhimurium
  • fungal cells such as yeast
  • plant cells such as fly S2 or Sf 9
  • animal cells such as CH0, COS, or Bowes s melanoma cells, etc. .
  • Transformation of a host cell with a DNA sequence described in the present invention or a recombinant vector containing the DNA sequence can be performed using conventional techniques well known to those skilled in the art.
  • the host is a prokaryote such as E. coli
  • competent cells capable of DNA uptake can be in the exponential growth phase were harvested, treated with CaC l 2 method used in steps well known in the art. The alternative is to use MgC l 2 .
  • transformation can also be performed by electroporation.
  • the following DNA transfection methods can be used: calcium phosphate co-precipitation method, or conventional mechanical methods such as microinjection, electroporation, and liposome packaging.
  • the medium used in the culture may be selected from various conventional mediums. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
  • a suitable method such as temperature conversion or chemical induction
  • the recombinant polypeptide may be coated in a cell, expressed on a cell membrane, or secreted outside the cell.
  • recombinant proteins can be isolated and purified by various separation methods using their physical, chemical, and other properties. These methods are well known to those skilled in the art. These methods include, but are not limited to: conventional renaturation treatment, protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
  • polypeptide of the present invention and the antagonists, agonists and inhibitors of the peptide can be directly used in the treatment of diseases, for example, it can treat malignant tumors, adrenal deficiency, skin diseases, various inflammations, HIV infections and immune diseases, etc. .
  • PKN / MK heparin-binding proteins are a class of extracellular heparin-binding proteins. These proteins are involved in the regulation of the growth and differentiation of various cells in the body. These proteins constitute a new family of heparin-binding proteins. Some growth regulators [Tsutsui J., et al., 1991]. The PKN / M heparin-binding protein family-specific conserved sequence is required to form its active mot if.
  • abnormal expression of the specific PKN / MK heparin-binding protein mot if will cause abnormal function of the polypeptide containing the mot if of the present invention, resulting in abnormal cell differentiation, proliferation, abnormal growth regulation of the body, and related diseases.
  • diseases such as tumors, embryonic development disorders, growth and development disorders.
  • heparin plays a very important role in the coagulation mechanism, the combination of heparin-binding protein and heparin can cause abnormal coagulation mechanisms and produce related diseases such as coagulopathy.
  • Coagulation disorders clotting factor deficiency, hemophilia A, hemophilia B, hereditary bleeding telangiectasia, allergic purpura, simple purpura, senile purpura, idiopathic thrombocytopenic purpura, regeneration Obstructive anemia, disseminated intravascular coagulation, myocardial infarction, cerebral thrombosis, pulmonary thrombosis
  • Embryonic disorders congenital abortion, cleft palate, limb loss, limb differentiation disorder, hyaline membrane disease, atelectasis, polycystic kidney, double ureter, cryptorchidism, congenital inguinal hernia, double uterus, vaginal atresia, suburethral Fissure, hermaphroditism, atrial septal defect, ventricular septal defect, pulmonary stenosis, arterial duct occlusion, neural tube defect, congenital hydrocephalus, iris defect, congenital cataract, congenital glaucoma or cataract, congenital deafness
  • Tumors of various tissues gastric cancer, liver cancer, lung cancer, esophageal cancer, breast cancer, leukemia, lymphoma, thyroid tumor, uterine fibroids, neuroblastoma, astrocytoma, ependymoma, glioblastoma, Colon cancer, melanoma, adrenal cancer, bladder cancer, bone cancer, osteosarcoma, myeloma, bone marrow cancer, brain cancer, uterine cancer, endometrial cancer, gallbladder cancer, colon cancer, thymic tumor, nasal cavity and sinus tumor, nose Pharyngeal cancer, Laryngeal cancer, Tracheal tumor, Fibroma, Fibrosarcoma, Lipoma, Liposarcoma, Leiomyoma
  • heparin-binding protein 10 of the present invention will also produce certain hereditary, hematological diseases and Diseases of the immune system, etc.
  • the polypeptide of the present invention and the antagonists, agonists and inhibitors of the polypeptide can be directly used in the treatment of diseases, for example, it can treat various diseases, especially coagulopathy, tumors, embryonic development disorders, growth and development disorders, and some inheritances. Sexual, hematological and immune system diseases.
  • Antagonists of heparin-binding protein 10 include antibodies, compounds, receptor deletions, and analogs that have been screened.
  • An antagonist of heparin-binding protein 10 can bind to and eliminate the function of heparin-binding protein 10, or inhibit the production of the polypeptide, or bind to the active site of the polypeptide so that the polypeptide cannot perform a biological function.
  • the present invention provides a method for producing antibodies using polypeptides, and fragments, derivatives, analogs or cells thereof as antigens. These antibodies can be polyclonal or monoclonal antibodies.
  • the invention also provides antibodies against heparin-binding protein 10 epitopes. These antibodies include (but are not limited to): Doklon antibodies, monoclonal antibodies, chimeric antibodies, single-chain antibodies, Fab fragments, and fragments from Fab expression libraries.
  • Polyclonal antibodies can be produced by injecting heparin-binding protein 10 directly into immunized animals (such as rabbits, mice, rats, etc.).
  • immunized animals such as rabbits, mice, rats, etc.
  • a variety of adjuvants can be used to enhance the immune response, including but not limited to Freund's adjuvant.
  • Techniques for preparing monoclonal antibodies to heparin-binding protein 10 include, but are not limited to, hybridoma technology (Kohler and Milstein. Nature, 1975, 256: 495-497), triple tumor technology, human beta-cell hybridoma technology, and EBV-hybridoma Technology, etc.
  • Chimeric antibodies that bind human constant regions to non-human-derived variable regions can be produced using existing techniques (Morrison et al, PNAS, 1985, 81: 6851).
  • the existing technology for producing single chain antibodies (US Pat No. 4946778) can also be used to produce single chain antibodies against heparin-binding protein 10.
  • Anti-heparin-binding protein 10 antibodies can be used in immunohistochemical techniques to detect heparin-binding protein 10 in biopsy specimens.
  • Monoclonal antibodies that bind to heparin-binding protein 10 can also be labeled with radioisotopes and injected into the body to track their location and distribution. This radiolabeled antibody can be used as a non-invasive diagnostic method to locate tumor cells and determine whether there is metastasis.
  • Antibodies can also be used to design immunotoxins that target a particular part of the body.
  • a high-affinity monoclonal antibody of heparin-binding protein 10 can covalently bind to bacterial or plant toxins (such as diphtheria toxin, ricin, ormosine, etc.).
  • a common method is to attack the amino group of an antibody with a thiol cross-linking agent such as SPDP and bind the toxin to the antibody through the exchange of disulfide bonds.
  • This hybrid antibody can be used to kill heparin-binding protein 10-positive cells.
  • the invention also relates to a diagnostic test method for quantitatively and locally detecting the level of heparin-binding protein 10.
  • tests are well known in the art and include FISH assays and radioimmunoassays.
  • the levels of heparin-binding protein 10 detected in the test can be used to explain the importance of heparin-binding protein 10 in various diseases and to diagnose diseases in which heparin-binding protein 10 plays a role.
  • polypeptide of the present invention can also be used for peptide mapping analysis.
  • the polypeptide can be specifically cleaved by physical, chemical or enzymatic analysis, and subjected to one-dimensional or two-dimensional or three-dimensional gel electrophoresis analysis, and more preferably mass spectrometry analysis.
  • Polynucleotides encoding heparin-binding protein 10 can also be used for a variety of therapeutic purposes. Gene therapy technology can be used to treat abnormal cell proliferation, development or metabolism caused by the non-expression or abnormal / inactive expression of heparin-binding protein 10.
  • Recombinant gene therapy vectors (such as viral vectors) can be designed to express variant heparin-binding protein 10 to inhibit endogenous heparin-binding protein 10 activity.
  • a variant heparin-binding protein 10 may be a shortened heparin-binding protein 10 lacking a signaling domain, and although it can bind to downstream substrates, it lacks signaling activity.
  • recombinant gene therapy vectors can be used to treat diseases caused by abnormal expression or activity of heparin-binding protein 10.
  • Virus-derived expression vectors such as retrovirus, adenovirus, adenovirus-associated virus, herpes simplex virus, parvovirus, etc. can be used to transfer a polynucleotide encoding a heparin-binding protein 10 into a cell.
  • a method for constructing a recombinant viral vector carrying a polynucleotide encoding a heparin-binding protein 10 can be found in the existing literature (Sambrook, et al.).
  • a recombinant polynucleotide encoding heparin-binding protein 10 can be packaged into liposomes and transferred into cells.
  • Methods for introducing a polynucleotide into a tissue or cell include: injecting the polynucleotide directly into a tissue in vivo; or introducing the polynucleotide into a cell through a vector (such as a virus, phage, or plasmid) in vitro, The cells are then transplanted into the body and the like.
  • a vector such as a virus, phage, or plasmid
  • Oligonucleotides including antisense RNA and DM
  • ribozymes that inhibit heparin-binding protein 10 mRNA are also within the scope of the present invention.
  • a ribozyme is an enzyme-like RNA molecule that specifically decomposes specific RNA. Its mechanism of action is that the ribozyme molecule specifically hybridizes with a complementary target RNA for endonucleation.
  • Antisense NA, DNA, and ribozymes can be obtained using any existing RNA or DM synthesis techniques, such as solid-phase phosphate amide chemical synthesis to synthesize oligonucleotides.
  • Antisense RNA molecules can be obtained by in vitro or in vivo transcription of DM sequences encoding the RNA.
  • This DNA sequence has been integrated downstream of the RNA polymerase promoter of the vector.
  • it can be modified in a variety of ways, such as increasing the sequence length on both sides, and the linkage between ribonucleosides using phosphorothioate or peptide bonds instead of phosphodiester bonds.
  • the polynucleotide encoding heparin-binding protein 10 can be used for the diagnosis of diseases related to heparin-binding protein 10.
  • the polynucleotide encoding heparin-binding protein 10 can be used to detect the expression of heparin-binding protein 10 or the abnormal expression of heparin-binding protein 10 in a disease state.
  • the DNA sequence encoding heparin-binding protein 10 can be used to hybridize biopsy specimens to determine the expression of heparin-binding protein 10.
  • Hybridization techniques include Southern blotting, Northern blotting, and in situ hybridization. These techniques and methods are publicly available and mature, and related kits are commercially available.
  • a part or all of the polynucleotide of the present invention can be used as a probe to be fixed on a microarray (Microarray) or a DNA chip (also referred to as a "gene chip") for analyzing differential expression analysis and gene diagnosis of genes in tissues.
  • Heparin-binding protein 10 specific primers can also be used to detect the transcription products of heparin-binding protein 10 by RNA-polymerase chain reaction (RT-PCR) in vitro amplification.
  • Detection of mutations in the heparin-binding protein 10 gene can also be used to diagnose heparin-binding protein 10-related diseases.
  • Heparin-binding protein 10 mutations include point mutations, translocations, deletions, recombinations, and any other abnormalities compared to the normal wild-type heparin-binding protein 10 DNA sequence. Mutations can be detected using existing techniques such as Southern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, mutations may affect protein expression, so Northern blotting and Western blotting can be used to indirectly determine whether a gene is mutated.
  • sequences of the invention are also valuable for chromosome identification. This sequence will specifically target a specific position on a human chromosome and can hybridize to it. Currently, specific sites for each gene on the chromosome need to be identified. Currently, only a few chromosome markers based on actual sequence data (repeating polymorphisms) are available for marking chromosome positions. According to the present invention, in order to associate these sequences with disease-related genes, an important first step is to locate these DNA sequences on a chromosome.
  • PCR primers (preferably 15-35bp) are prepared based on the cDNA, which can be used to position the sequence for staining. Heterozygous cells that contain human genes corresponding to the primers produce amplified fragments.
  • the PCR bit method for somatic hybrid cells is a quick way to locate DNA to a specific chromosome.
  • oligonucleotide primers of the present invention in a similar manner, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization.
  • Other similar strategies that can be used for chromosomal localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and pre-selection of hybridization to construct chromosome-specific cDNA libraries.
  • Fluorescent in situ hybridization of cDNA clones with metaphase chromosomes allows precise chromosomal localization in one step.
  • FISH Fluorescent in situ hybridization
  • the difference in cDNA or genomic sequence between the affected and unaffected individuals needs to be determined. If a mutation is observed in some or all diseased individuals and the mutation is not observed in any normal individuals, the mutation may be the cause of the disease. Comparing affected and unaffected individuals usually involves first looking for structural changes in chromosomes, such as deletions or translocations that are visible at the chromosomal level or detectable with cDNA sequence-based PCR. According to the resolution capabilities of current physical mapping and gene mapping technology, the cDNA accurately mapped to the chromosomal region associated with the disease can be one of 50 to 500 potentially pathogenic genes (assuming 1 megabase mapping resolution) Capacity and each 20kb corresponds to a gene).
  • the polypeptides, polynucleotides and mimetics, agonists, antagonists and inhibitors of the present invention can be used in combination with a suitable pharmaceutical carrier.
  • suitable pharmaceutical carrier can be water, glucose, ethanol, salts, buffers, glycerol, and combinations thereof.
  • the composition comprises a safe and effective amount of the polypeptide or antagonist, and carriers and excipients which do not affect the effect of the drug. These compositions can be used as drugs for the treatment of diseases.
  • the invention also provides a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
  • a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention.
  • these containers there may be instructional instructions given by government agencies that manufacture, use, or sell pharmaceuticals or biological products, which prompts permission for administration on the human body by government agencies that produce, use, or sell.
  • the polypeptides of the invention can be used in combination with other therapeutic compounds.
  • the pharmaceutical composition can be administered in a convenient manner, such as by a topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal route of administration.
  • Heparin-binding protein 10 to effectively treat and / or prevent specific The amount of indication to be administered.
  • the amount and range of heparin binding protein 10 administered to a patient will depend on many factors, such as the mode of administration, the health conditions of the person to be treated, and the judgment of the diagnostician.
  • Total human fetal brain RNA was extracted with guanidine isothiocyanate / amidine / chloroform in one step.
  • Poly (A) mRNA was isolated from total RNA using the Quik mRNA Isolation Kit (Qiegene). 2ug poly (A) mRNA is reverse transcribed to form cDNA.
  • a Smart cDM cloning kit (purchased from Clontech) was used to insert the cDNA fragment into the multicloning site of the pBSK (+) vector (Clontech) to transform DH5a. The bacteria formed a cDNA library.
  • Dye terminate cycle reaction sequencing kit Perkin-Elmer
  • ABI 377 automatic sequencer Perkin-Elmer
  • the determined cDNA sequence was compared with the existing public D sequence database (Genebank), and it was found that the cDNA sequence of one of the clones 0660D02 was the new D.
  • the inserted cDNA fragments contained in this clone were determined in both directions by synthesizing a series of primers.
  • CDNA was synthesized using fetal brain total RNA as a template and oligo-dT as a primer for reverse transcription reaction. After purification with Qiagene's kit, the following primers were used for PCR amplification: Primer 1: 5'- AAATGTAAGAAAATATCAGGCACC -3 '(SEQ ID NO: 3) Primer2: 5'- TTCTTTATGTGGCTTGCTGTTTGC -3' (SEQ ID NO: 4)
  • Primer2 is the 3, terminal reverse sequence of SEQ ID NO: 1.
  • Conditions for the amplification reaction 50 mmol / L KCI, 10 mmol / L Tris-HCl, pH 8.5, 1.5 mmol / L MgCl 2 , 200 ⁇ 1/1 dNTP, lOpmol primer, 1U Taq DM polymerase (Clontech).
  • the reaction was performed on a PE9600 DM thermal cycler (Perkin-Elmer) for 25 cycles under the following conditions: 94. C 30sec; 55 ° C 30sec; 72 ° C 2min 0
  • set ⁇ -actin as a positive control and template blank as a negative control during RT-PCR.
  • the amplified product was purified using a QIAGEN kit, and ligated to a pCR vector (Invitrogen product) using a TA cloning kit.
  • the DNA sequence analysis results showed that the DNA sequence of the PCR product was exactly the same as that of 1 to 1865 bp shown in SEQ ID NO: 1.
  • This method involves acid guanidinium thiocyanate phenol-chloroform extraction. That is, 4M guanidine isothiocyanate-25mM sodium citrate, 0.2M sodium acetate (pH4.0) were used to uniformly paddle the tissue, and 1 volume of phenol and 1/5 volume of chloroform-isoamyl alcohol (49: 1) were added. ), Mix and centrifuge. Aspirate the aqueous layer, add isopropanol (0.8 vol) and centrifuge the mixture to obtain RNA precipitate. The resulting RNA pellet was washed with 70% ethanol, dried and dissolved in water.
  • a 32P-labeled probe (approximately 2 x 10 6 cpm / ml) was hybridized with a nitrocellulose membrane to which RNA was transferred at 42 ° C overnight in a solution containing 50% formamide-25mM KH 2 P0 4 ( P H7.4) -5 ⁇ SSC-5 ⁇ Denhardt's solution and 20 ⁇ g / ml salmon sperm DNA. After hybridization, the filter was washed in lx SSC-0.1% SDS at 55 ° C for 30 minutes. Then, use Analysis and quantification using Phosphor Imager.
  • Example 5 In vitro expression, isolation and purification of recombinant heparin-binding protein 10
  • Primer3 5'- CCCCATATGATGTCCCTCCAGTTCAAAATCAAC -3 '(Seq ID No: 5)
  • Primer 4 5'- CCCGAGCTCTTACCATCTTCTGCAATCAAGTGA -3 '(Seq ID No: 6)
  • the 5' ends of these two primers contain Ndel and Sacl digestion sites, respectively, followed by the 5 'end and 3.
  • the coding sequence at the end, the Ndel and Sacl restriction sites correspond to the selective endonuclease sites on the expression vector plasmid pET-28b (+) (Novagen, Cat. No. 69865. 3).
  • the pBS-0660D02 plasmid containing the full-length target gene was used as a template for the PCR reaction.
  • the PCR reaction conditions were as follows: 10 pg of plasmid pBS-0660D02, primers Primer-3 and Primer-4 in 50 ⁇ 1 total volume, 1 J Opmol, Advantage polymerase Mi x
  • Cycle parameters 94 ° C 20s, 60 ° C 30s, 68 ° C 2 min, a total of 25 cycles.
  • Ndel and Sacl were used to double digest the amplified product and plasmid pET-28 (+), respectively, and large fragments were recovered and ligated with T4 ligase.
  • the ligation product was transformed into Ca. bacillus DH5o by the calcium chloride method.
  • the final concentration of 3 ( ⁇ g / ml) was cultured overnight in a 1 ⁇ plate.
  • the positive clones were screened by colony PCR and sequenced.
  • the positive clones (PET-0660D02) with the correct sequence were selected and the recombinant plasmid was transformed by the calcium chloride method.
  • the host strain BL21 was cultured at 37 ° C to logarithm.
  • Polypeptide synthesizer (product of PE company) was used to synthesize the following specific peptides of heparin-binding protein 10: -Glu-C00H (SEQ ID NO: 7).
  • the polypeptide is coupled to hemocyanin and bovine serum albumin to form a complex.
  • Rabbits were immunized with 4 mg of the hemocyanin polymorphic complex plus complete Freund's adjuvant, and 15 days later, the hemocyanin polypeptide complex plus incomplete Freund's adjuvant was used to boost immunity once.
  • a titer plate coated with a 15 g / ml bovine serum albumin peptide complex was used as an ELISA to determine antibody titers in rabbit serum.
  • Total IgG was isolated from antibody-positive rabbit sera using protein A-Sepharose.
  • the peptide was bound to a cyanogen bromide-activated Sepharose4B column, and anti-peptide antibodies were separated from the total IgG by affinity chromatography.
  • the immunoprecipitation method demonstrated that the purified antibody specifically binds to heparin-binding protein 10.
  • the probes can be used to hybridize to the genome or CDM library of normal tissue or pathological tissue from different sources.
  • the probe can further be used to detect the polynucleotide sequence of the present invention or its homologous polynucleotide sequence in normal tissue or Whether the expression in pathological tissue cells is abnormal.
  • the purpose of this embodiment is to select a suitable oligonucleotide fragment from the polynucleotide SEQ ID NO: 1 of the present invention as a hybridization probe, and to identify whether some tissues contain the polynucleoside of the present invention by a filter hybridization method.
  • Filter hybridization methods include dot blotting, Southern imprinting, Nor thern blotting, and copying methods. They all use the same steps to fix the polynucleotide sample to be tested on the filter and then hybridize.
  • the sample-immobilized filter is first pre-hybridized with a probe-free hybridization buffer to saturate the non-specific binding site of the sample on the filter with the carrier and the synthesized polymer.
  • the pre-hybridization solution is then replaced with a hybridization buffer containing labeled probes and incubated to hybridize the probes to the target nucleic acid.
  • the unhybridized probes are removed by a series of membrane washing steps.
  • This embodiment uses higher-intensity washing conditions (such as lower salt concentration and higher temperature) to reduce the hybridization background and retain only strong specific signals.
  • oligonucleotide fragments for use as hybridization probes from the polynucleotide SEQ ID NO: 1 of the present invention should follow the following principles and several aspects to be considered:
  • Those that meet the above conditions can be used as primary selection probes, and then further computer sequence analysis, including the primary selection probe and its source sequence region (ie, SEQ ID NO: 1) and other known genomic sequences and their complements The regions are compared for homology. If the homology with the non-target molecular region is greater than 85% or there are more than 15 consecutive bases, the primary probe should not be used;
  • Probe 1 (probel), which belongs to the first type of probe, is completely homologous or complementary to the gene fragment of SEQ ID NO: 1 (41Nt) 5'- TGTCCCTCCAGTTCAAAATCAACCTHCGAAAACAAAACAA -3 '(SEQ ID NO: 8)
  • Probe 2 (probe2), which belongs to the second type of probe, is equivalent to the replacement mutant sequence of the gene fragment of SEQ ID NO: 1 or its complementary fragment (41Nt):
  • PBS phosphate buffered saline
  • step 8-13 are only used when contamination must be removed, otherwise step 14 can be performed directly.
  • NC membrane nitrocellulose membrane
  • the sample membrane was placed in a plastic bag, and 3-1 Omg pre-hybridization solution (OxDenhardf s; 6xSSC, 0.1 mg / ml CT DM (calf thymus DNA)) was added. After sealing the bag, shake at 68 ° C for 2 hours.
  • 3-1 Omg pre-hybridization solution OxDenhardf s; 6xSSC, 0.1 mg / ml CT DM (calf thymus DNA)
  • Gene chip or gene micro matrix (DNA Mi croarray) is a new technology that many national laboratories and large pharmaceutical companies are currently developing and developing. It refers to the orderly and high density arrangement of a large number of target gene fragments on glass. , Silicon and other carriers, and then use fluorescence detection and computer software to compare and analyze the data, in order to achieve the purpose of rapid, efficient, high-throughput analysis of biological information.
  • the polynucleotide of the present invention can be used as Targeting D for gene chip technology for high-throughput research on new gene functions; finding and screening new tissue-specific genes, especially new genes related to diseases such as tumors; diagnosis of diseases such as hereditary diseases. The specific method steps have been reported in the literature.
  • a total of 4,000 polynucleotide sequences of various full-length cDNAs are used as target DNA, including the polynucleotide of the present invention. They were respectively amplified by PCR. After purification, the concentration of the amplified product was adjusted to about 500 ng / ul, and spotted on a glass medium with a Cartesian 7500 spotter (purchased from Cartesian Company, USA). The distance between them is 280 ⁇ . The spotted slides were hydrated, dried, and cross-linked in a UV cross-linker. After elution, the slides were fixed to D to fix the slides to prepare chips. The specific method steps have been reported in the literature. The sample post-processing steps in this embodiment are:
  • Total mRNA was extracted from normal and cancer cells in one step, and mRNA was purified using Oligotex mRNA Midi Kit (purchased from QiaGen).
  • the fluorescent reagent Cy3dUTP (5- Amino- propargy 1-2 '- deoxyuri dine 5'-tripha te coupled to C 3 f luorescent dye, purchased from Amersham Phamacia Biotech Company, labeled mRNA of normal tissues, using a fluorescent reagent Cy5dUTP (5-Araino-propargy 1-2 '-deoxyur i dine 5'-tr iphate coupled to Cy5 fluorescent dye (purchased from Amersham Phamac ia Biotech)) labeled ⁇ 3 ⁇ 4 tissue mRNA, and the probe was prepared after purification.
  • Cy3dUTP 5- Amino- propargy 1-2 '- deoxyuri dine 5'-tripha te coupled to C 3 f luorescent dye, purchased from Am

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention discloses a new polypeptide-heparin bind protein 10, the polynucleotide encoding it and a method producing the polypeptide by recombinant DNA technology. The present invention further discloses a method using the polypeptide to treat various disorders, e.g. malignant neoplasm, hematopathy, HIV infection and immunological disease and various inflammation etc. The present invention also discloses an agonist of the polypeptide and its therapeutic use. The present invention further discloses the use of the polynucleotide encoding the new heparin bind protein 10.

Description

一种新的多肽——肝素结合蛋白 10和编码这种多肽的多核苷酸  A new polypeptide, heparin-binding protein 10, and a polynucleotide encoding the polypeptide
#术领域 # 术 领域
本发明属于生物技术领域, 具体地说, 本发明描述了一种新的多肽——肝素结 合蛋白 10, 以及编码此多肽的多核苷酸序列。 本发明还涉及此多核苷酸和多肽的 制备方法和应用。  The present invention belongs to the field of biotechnology. Specifically, the present invention describes a novel polypeptide, heparin binding protein 10, and a polynucleotide sequence encoding the polypeptide. The invention also relates to the preparation method and application of the polynucleotide and polypeptide.
技术背景 technical background
在生物体内含有一类细胞外肝素结合蛋白, 这些蛋白在生物体内涉及各种细 胞的生长与分化调控过程, 这类蛋白构成了一新的肝素结合蛋白家族, 该家族的 成员均为一些生长调节因子 [Tsutsui J. , Uehara K. et a l., 1991, Bi ochem Biophys Res Commun, 176: 792-797]。 不同来源的该家族的成员均含有较高的序 列同源性。  It contains a class of extracellular heparin-binding proteins in the body. These proteins are involved in the regulation of the growth and differentiation of various cells in the body. This type of protein constitutes a new heparin-binding protein family. All members of this family are some of the growth regulators. Factors [Tsutsui J., Uehara K. et al., 1991, Biochem Biophys Res Commun, 176: 792-797]. Members of this family from different sources all have high sequence homology.
这些生长调节因子是一些高度相关的蛋白, 约有 140 个氨基酸残基组成, 且 这些蛋白均含有 10个保守的涉及二硫键形成的半胱氨酸残基。 该蛋白家族成员的 蛋白序列中还富含一些基础氨基酸残基和色氨酸。 其含 10个保守的半胱氨酸残基 的区域如下所示:  These growth regulators are highly related proteins consisting of approximately 140 amino acid residues, and each of these proteins contains 10 conserved cysteine residues involved in the formation of disulfide bonds. The protein sequence of members of this protein family is also rich in some basic amino acid residues and tryptophan. The region containing 10 conserved cysteine residues is shown below:
XXXXXXXCXXXCXXXCXXXXXCXXXCXCXXXXCXXXXCXXXXXXXXXXCXXXXCXXXXXXXXXXXXX  XXXXXXXCXXXCXXXCXXXXXCXXXCXCXXXXCXXXXCXXXXXXXXXXCXXXXCXXXXXXXXXXXXX
氺 # * * ** ** * * * * ** *  氺 # * * ** ** * * * * ** *
'c':为保守的半胱氨酸残基, 可能涉及二硫键的形成。 'c' : Conserved cysteine residues, which may be involved in the formation of disulfide bonds.
'*':为两个保守的一致性序列片段的位点。  '*': Sites for two conservative consensus sequence fragments.
研究发现, 该生长因子家族成员的蛋白序列中含有两个保守的序列片段, 这 两个一致性序列片段如下所示. - 序列片段 1 : S- [DE] -C-X- [DE] -W-X-W-X ( 2 ) -C-X-P-X- [SN] -X-D-C-G- [LIVMA] -G-X-R-E-G;  The study found that the protein sequence of this growth factor family member contains two conserved sequence fragments, and these two consensus sequence fragments are shown below.-Sequence fragment 1: S- [DE] -CX- [DE] -WXWX ( 2) -CXPX- [SN] -XDCG- [LIVMA] -GXREG;
序列片段 2: C- [ R] - [LIVM] -P-C-N-W-K-K-X-F-G-A- [DE] -C- -Y-X-F- [EQ] - X-W-G-X-C;  Sequence fragment 2: C- [R]-[LIVM] -P-C-N-W-K-K-X-F-G-A- [DE] -C- -Y-X-F- [EQ]-X-W-G-X-C;
这两个序列片段均含有大量的半胱氨酸残基, 且在所有的家族成员中均存在。 该序列片段可能是蛋白与其它蛋白结合并发挥其生长调节功能的重要活性区域, 该两个片段的突变都将影响蛋白在生物体内发挥正常的生理功能。 该蛋白家族的 成员在生物体内涉及各种细胞分化及生长的重要调节过程, 该类蛋白的表达异常 将导致生物体一些相关代谢途径的异常。 该蛋白的表达异常通常与生物体内各种 发育代谢紊乱症、 一些肿瘤及癌症等疾病的发生相关。 由于如上所述肝素结合蛋白 10蛋白在机体重要功能中起重要作用, 而且相信 这些调节过程中涉及大量的蛋白, 因而本领域中一直需要鉴定更多参与这些过程 的肝素结合蛋白 1 0蛋白, 特别是鉴定这种蛋白的氨基酸序列。 新肝素结合蛋白 10 蛋白编码基因的分离也为研究确定该蛋白在健康和疾病状态下的作用提供了基 础。 这种蛋白可能构成开发疾病诊断和 /或治疗药的基础, 因此分离其编码 DNA是 非常重要的。 Both of these sequence fragments contain a large number of cysteine residues and are present in all family members. This sequence fragment may be an important active region where the protein binds to other proteins and exerts its growth regulating function. Mutations of these two fragments will affect the protein's normal physiological function in vivo. Members of this protein family are involved in important regulatory processes of cell differentiation and growth in the body, and abnormal expression of such proteins will cause some of the organism's related metabolic pathways to be abnormal. The abnormal expression of this protein is usually related to the occurrence of various developmental metabolic disorders, some tumors and cancers in the body. As the heparin binding protein 10 protein plays an important role in the important functions of the body as described above, and it is believed that a large number of proteins are involved in these regulatory processes, there has been a need in the art to identify more heparin binding protein 10 proteins involved in these processes, especially Is to identify the amino acid sequence of this protein. Isolation of the neoheparin-binding protein 10 protein-encoding gene also provides a basis for research to determine the role of this protein in health and disease states. This protein may form the basis for the development of diagnostic and / or therapeutic drugs for diseases, so it is important to isolate its coding DNA.
发明目的 Object of the invention
本发明的一个目的是提供分离的新的多肽——肝素结合蛋白 10 以及其片段、 类似物和衍生物。  It is an object of the present invention to provide an isolated novel polypeptide, heparin-binding protein 10, and fragments, analogs and derivatives thereof.
本发明的另一个目的是提供编码该多肽的多核苷酸。  Another object of the invention is to provide a polynucleotide encoding the polypeptide.
本发明的另一个目的是提供含有编码肝素结合蛋白 1 0 的多核苷酸的重组载 体。  Another object of the present invention is to provide a recombinant vector containing a polynucleotide encoding a heparin-binding protein 10.
本发明的另一个目的是提供含有编码肝素结合蛋白 1 0的多核苷酸的基因工程 化宿主细胞。  Another object of the present invention is to provide a genetically engineered host cell containing a polynucleotide encoding a heparin-binding protein 10.
本发明的另一个目的是提供生产肝素结合蛋白 10的方法。  Another object of the present invention is to provide a method for producing heparin-binding protein 10.
本发明的另一个目的是提供针对本发明的多肽——肝素结合蛋白 10的抗体。 本发明的另一个目的是提供了针对本发明多肽——肝素结合蛋白 1 0 的模拟化 合物、 拮抗剂、 激动剂、 抑制剂。  Another object of the present invention is to provide an antibody against the polypeptide of the present invention, heparin-binding protein 10. Another object of the present invention is to provide mimic compounds, antagonists, agonists, and inhibitors directed to the polypeptide of the present invention, heparin binding protein 10.
本发明的另一个目的是提供诊断治疗与肝素结合蛋白 10异常相关的疾病的方 法。  Another object of the present invention is to provide a method for diagnosing and treating diseases related to abnormalities in heparin binding protein 10.
发明概要 Summary of invention
本发明涉及一种分离的多肽, 该多肽是人源的, 它包含: 具有 SEQ ID No. 2 氨基酸序列的多肽、 或其保守性变体、 生物活性片段或衍生物。 较佳地, 该多肽 是具有 SEQ ID NO: 2氨基酸序列的多肽。  The present invention relates to an isolated polypeptide, which is of human origin and comprises: a polypeptide having the amino acid sequence of SEQ ID No. 2, or a conservative variant, biologically active fragment or derivative thereof. Preferably, the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: 2.
本发明还涉及一种分离的多核苷酸, 它包含选自下组的一种核苷酸序列或其 变体:  The invention also relates to an isolated polynucleotide comprising a nucleotide sequence or a variant thereof selected from the group consisting of:
(a)编码具有 SEQ ID No. 2氨基酸序列的多肽的多核苷酸;  (a) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID No. 2;
(b)与多核苷酸 (a)互补的多核苷酸;  (b) a polynucleotide complementary to polynucleotide (a);
(c)与(a)或(b)的多核苷酸序列具有至少 70%相同性的多核苷酸。  (c) A polynucleotide having at least 70% identity to a polynucleotide sequence of (a) or (b).
更佳地, 该多核苷酸的序列是选自下组的一种: (a)具有 SEQ I D NO: 1 中 343- 618位的序列; 和(b)具有 SEQ ID NO: 1中 1-1865位的序列。  More preferably, the sequence of the polynucleotide is one selected from the group consisting of: (a) a sequence having positions 343-618 in SEQ ID NO: 1; and (b) a sequence having 1-1865 in SEQ ID NO: 1 Sequence of bits.
本发明另外涉及一种含有本发明多核苷酸的载体, 特别是表达载体; 一种用 该载体遗传工程化的宿主细肐, 包括转化、 转导或转染的宿主细胞; 一种包括培 养所述宿主细胞和回收表达产物的制备本发明多肽的方法。 The invention further relates to a vector, in particular an expression vector, containing a polynucleotide of the invention; The vector genetically engineered host cell includes a transformed, transduced or transfected host cell; a method for preparing a polypeptide of the present invention comprising culturing the host cell and recovering an expression product.
本发明还涉及一种能与本发明多肽特异性结合的抗体。  The invention also relates to an antibody capable of specifically binding to a polypeptide of the invention.
本发明还涉及一种筛选的模拟、 激活、 拮抗或抑制肝素结合蛋白 1 0蛋 ό活性 的化合物的方法, 其包括利用本发明的多肽。 本发明还涉及用该方法获得的化合 物。  The present invention also relates to a method for screening compounds that mimic, activate, antagonize or inhibit the activity of heparin-binding protein 100, which comprises utilizing the polypeptide of the present invention. The invention also relates to compounds obtained by this method.
本发明还涉及一种体外检测与肝素结合蛋白 1 0 蛋白异常表达相关的疾病或 疾病易感性的方法, 包括检测生物样品中所述多肽或其编码多核苷酸序列中的突 变, 或者检测生物样品中本发明多肽的量或生物活性。  The invention also relates to a method for in vitro detection of a disease or susceptibility to disease associated with abnormal expression of a heparin-binding protein 10 protein, comprising detecting a mutation in the polypeptide or a sequence encoding a polynucleotide thereof in a biological sample, or detecting a biological sample. The amount or biological activity of a polypeptide of the invention.
本发明也涉及一种药物组合物, 它含有本发明多肽或其模拟物、 激活剂、 拮 抗剂或抑制剂以及药学上可接受的载体。  The invention also relates to a pharmaceutical composition comprising a polypeptide of the invention or a mimetic thereof, an activator, an antagonist or an inhibitor, and a pharmaceutically acceptable carrier.
本发明还涉及本发明的多肽和 /或多核苷酸在制备用于治疗癌症、 发育性疾病 或免疫性疾病或其它由于肝素结合蛋白 1 0表达异常所引起疾病的药物的用途。  The present invention also relates to the use of the polypeptide and / or polynucleotide of the present invention in the preparation of a medicament for treating cancer, developmental disease or immune disease or other diseases caused by abnormal expression of heparin binding protein 10.
本发明的其它方面由于本文的技术的公开, 对本领域的技术人员而言是显而 易见的。  Other aspects of the invention will be apparent to those skilled in the art from the disclosure of the techniques herein.
附图说明 BRIEF DESCRIPTION OF THE DRAWINGS
下列附图用于说明本发明的具体实施方案, 而不用于限定由权利要求书所 界定的本发明范围。  The following drawings are used to illustrate specific embodiments of the invention, but not to limit the scope of the invention as defined by the claims.
图 1是本发明肝素结合蛋白 1 0在 共 71个氨基酸和肝素结合蛋白特征性 结构域的氨基酸序列同源性比较图。 上方序列是肝素结合蛋白 1 0 , 下方序列是 肝素结合蛋白特征性结构域。 Ί " 和 " : " 及 ". " 表示在两个序列间同一氨 基酸出现的概率依次减小。  Fig. 1 is a comparison diagram of the amino acid sequence homology of a total of 71 amino acids of heparin-binding protein 10 of the present invention and characteristic domains of heparin-binding protein. The upper sequence is heparin-binding protein 10, and the lower sequence is the characteristic domain of heparin-binding protein. Ί "and": "and". "Indicate that the probability of the same amino acid decreasing between the two sequences decreases in order.
图 2为分离的肝素结合蛋白 1 0的聚丙烯酰胺凝胶电泳图(SDS- PAGE )。 Kkda 为蛋白质的分子量。 箭头所指为分离出的蛋白条带。  Figure 2 shows the polyacrylamide gel electrophoresis (SDS-PAGE) of the isolated heparin-binding protein 10. Kkda is the molecular weight of the protein. The arrow indicates the isolated protein band.
发明内容 Summary of the Invention
本说明书和权利要求书中使用的下列术语除非特别说明具有如下的含义: "核酸序列" 是指寡核苷酸、 核苷酸或多核苷酸及其片段或部分, 也可以指 基因组或合成的 DNA或 RNA , 它们可以是单链或双链的, 代表有义链或反义链。 类 似地, 术语 "氨基酸序列" 是指寡肽、 肽、 多肽或蛋白质序列及其片段或部分。 当本发明中的 "氨基酸序列" 涉及一种天然存在的蛋白质分子的氨基酸序列时, 这种 "多肽" 或 "蛋白质" 不意味着将氨基酸序列限制为与所述蛋白质分子相关 的完整的天然氨基酸。 蛋白质或多核苷酸 "变体" 是指一种具有一个或多个氨基酸或核苷酸改变的 氨基酸序列或编码它的多核苷酸序列。 所述改变可包括氨基酸序列或核苷酸序列 中氨基酸或核苷酸的缺失、 插入或替换。 变体可具有 "保守性" 改变, 其中替换 的氨基酸具有与原氨基酸相类似的结构或化学性质, 如用亮氨酸替换异亮氨酸。 变体也可具有非保守性改变, 如用色氨酸替换甘氨酸。 The following terms used in this specification and claims have the following meanings unless specifically stated: "Nucleic acid sequence" refers to an oligonucleotide, a nucleotide or a polynucleotide and a fragment or part thereof, and may also refer to a genomic or synthetic DNA or RNA, they can be single-stranded or double-stranded, representing the sense or antisense strand. Similarly, the term "amino acid sequence" refers to an oligopeptide, peptide, polypeptide or protein sequence and fragments or portions thereof. When the "amino acid sequence" in the present invention relates to the amino acid sequence of a naturally occurring protein molecule, such "polypeptide" or "protein" does not mean to limit the amino acid sequence to a complete natural amino acid related to the protein molecule . A protein or polynucleotide "variant" refers to an amino acid sequence having one or more amino acids or nucleotide changes, or a polynucleotide sequence encoding it. The changes may include deletions, insertions or substitutions of amino acids or nucleotides in the amino acid sequence or nucleotide sequence. Variants may have "conservative" changes in which the substituted amino acid has a structural or chemical property similar to the original amino acid, such as replacing isoleucine with leucine. Variants can also have non-conservative changes, such as replacing glycine with tryptophan.
"缺失" 是指在氨基酸序列或核苷酸序列中一个或多个氨基酸或核苷酸的缺 失。  "Deletion" refers to the deletion of one or more amino acids or nucleotides in an amino acid sequence or nucleotide sequence.
"插入" 或 "添加" 是指在氨基酸序列或核苷酸序列中的改变导致与天然存 在的分子相比, 一个或多个氨基酸或核苷酸的增加。 "替换" 是指由不同的氨基酸 或核苷酸替换一个或多个氨基酸或核苷酸。  "Insertion" or "addition" means that a change in the amino acid sequence or nucleotide sequence results in an increase in one or more amino acids or nucleotides compared to a molecule that exists in nature. "Replacement" refers to the replacement of one or more amino acids or nucleotides with different amino acids or nucleotides.
"生物活性" 是指具有天然分子的结构、 调控或生物化学功能的蛋白质。 类 似地, 术语 "免疫学活性" 是指天然的、 重组的或合成蛋白质及其片段在合适的 动物或细胞中诱导特定免疫反应以及与特异性抗体结合的能力。  "Biological activity" refers to a protein that has the structure, regulation, or biochemical function of a natural molecule. Similarly, the term "immunologically active" refers to the ability of natural, recombinant or synthetic proteins and fragments thereof to induce a specific immune response and to bind specific antibodies in a suitable animal or cell.
"激动剂" 是指当与肝素结合蛋白 1 0结合时, 一种可引起该蛋白质改变从而 调节该蛋白质活性的分子。 激动剂可以包括蛋白质、 核酸、 碳水化合物或任何其 它可结合肝素结合蛋白 1 0的分子。  An "agonist" refers to a molecule that, when bound to a heparin-binding protein 10, causes the protein to change, thereby regulating the activity of the protein. An agonist may include a protein, a nucleic acid, a carbohydrate, or any other molecule that can bind heparin binding protein 10.
"拮抗剂" 或 "抑制物" 是指当与肝素结合蛋白 1 0结合时, 一种可封闭或调 节肝素结合蛋白 1 0的生物学活性或免疫学活性的分子。 拮抗剂和抑制物可以包括 蛋白质、 核酸、 碳水化合物或任何其它可结合肝素结合蛋白 10的分子。  An "antagonist" or "inhibitor" refers to a molecule that can block or regulate the biological or immunological activity of heparin-binding protein 10 when bound to heparin-binding protein 10. Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, or any other molecule that can bind heparin-binding protein 10.
"调节" 是指肝素结合蛋白 1 0的功能发生改变, 包括蛋白质活性的升高或降 低、 结合特性的改变及肝素结合蛋白 1 0的任何其它生物学性质、 功能或免疫性质 的改变。  "Regulation" refers to a change in the function of heparin-binding protein 10, including an increase or decrease in protein activity, a change in binding characteristics, and any other biological, functional, or immune properties of heparin-binding protein 10.
"基本上纯' '是指基本上不含天然与其相关的其它蛋白、 脂类、 糖类或其它物 质。 本领域的技术人员能用标准的蛋白质纯化技术纯化肝素结合蛋白 1 0。 基本上 纯的肝素结合蛋白 10在非还原性聚丙烯酰胺凝胶上能产生单一的主带。 肝素结合 蛋白 1 0多肽的纯度可用氨基酸序列分析。  "Substantially pure '" means essentially free of other proteins, lipids, sugars or other substances with which it is naturally associated. Those skilled in the art can purify heparin-binding protein 10 using standard protein purification techniques. Basically pure The heparin binding protein 10 can generate a single main band on a non-reducing polyacrylamide gel. The purity of the heparin binding protein 10 polypeptide can be analyzed by amino acid sequence.
"互补的" 或 "互补" 是指在允许的盐浓度和温度条件下通过碱基配对的多 核苷酸天然结合。 例如, 序列 "C- T- G- A" 可与互补的序列 "G- A-C- T" 结合。 两 个单链分子之间的互补可以是部分的或全部的。 核酸链之间的互补程度对于核酸 链之间杂交的效率及强度有明显影响。  "Complementary" or "complementary" refers to the natural binding of polynucleotides by base-pairing under conditions of acceptable salt concentration and temperature. For example, the sequence "C-T-G-A" can be combined with the complementary sequence "G-A-C-T". The complementarity between two single-stranded molecules can be partial or complete. The degree of complementarity between nucleic acid strands has a significant effect on the efficiency and strength of hybridization between nucleic acid strands.
"同源性" 是指互补的程度, 可以是部分同源或完全同源。 "部分同源" 是指 一种部分互补的序列, 其至少可部分抑制完全互补的序列与靶核酸的杂交。 这种 杂交的抑制可通过在严格性程度降低的条件下进行杂交(Southern印迹或 Nor thern 印迹等) 来检测。 基本上同源的序列或杂交探针可竟争和抑制完全同源的序列与 靶序列在严格性程度降低的条件下的结合。 这并不意味严格性程度降低的条件允 许非特异性结合, 因为严格性程度降低的条件要求两条序列相互的结合为特异性 或选择性相互作用。 "Homology" refers to the degree of complementarity and can be partially homologous or completely homologous. "Partial homology" refers to a partially complementary sequence that at least partially inhibits hybridization of a fully complementary sequence to a target nucleic acid. This Inhibition of hybridization can be detected by performing hybridization (Southern blotting or Nor thern blotting, etc.) under conditions of reduced stringency. Substantially homologous sequences or hybridization probes can compete and inhibit the binding of completely homologous sequences to the target sequence under conditions of reduced stringency. This does not mean that the conditions of reduced stringency allow non-specific binding, because the conditions of reduced stringency require that the two sequences bind to each other as a specific or selective interaction.
"相同性百分率" 是指在两种或多种氨基酸或核酸序列比较中序列相同或相 似的百分率。 可用电子方法测定相同性百分率, 如通过 MEGALIGN程序 (Lasergene sof tware package, DNASTAR, Inc. , Madi son Wi s. )„ MEGALIGN程序可根据不同的 方法如 Clus ter法比较两种或多种序列(Hi ggins, D. G. 和 P. M. Sharp (1988) Gene 73: 237-244)。 Clus ter法通过检查所有配对之间的距离将各组序列排列成簇。 然后将各簇以成对或成组分配。 两个氨基酸序列如序列 A和序列 B之间的相同性百 分率通过下式计算:  "Percent identity" refers to the percentage of sequences that are the same or similar in the comparison of two or more amino acid or nucleic acid sequences. The percentage of identity can be determined electronically, such as through the MEGALIGN program (Lasergene sof tware package, DNASTAR, Inc., Madi son Wis.). The MEGALIGN program can compare two or more sequences (His ggins, DG and PM Sharp (1988) Gene 73: 237-244). The Clus ter method arranges groups of sequences into clusters by checking the distance between all pairs. The clusters are then assigned in pairs or groups. Two The percent identity between amino acid sequences such as sequence A and sequence B is calculated by the following formula:
序列 与序列 之间匹配的残基个数  Number of residues between sequence and sequence
序列 的残基数―序列 中间隔残基数 -序列 S中间隔残基数 X Residues sequences - sequences spacer residues - the sequence of residues X interval S
也可以通过 Clus ter法或用本领域周知的方法如 Jotun Hein 测定核酸序列之 间的相同性百分率(Hein J., (1990) Methods in enzymo logy 183: 625—645)。  The percent identity between nucleic acid sequences can also be determined by the Clus ter method or by methods known in the art such as Jotun Hein (Hein J., (1990) Methods in enzymo logy 183: 625-645).
"相似性" 是指氨基酸序列之间排列对比时相应位置氨基酸残基的相同或保 守性取代的程度。 用于保守性取代的氨基酸, 例如带负电荷的氨基酸可包括天冬 氨酸和谷氨酸; 带正电荷的氨基酸可包括赖氨酸和精氨酸; 具有不带电荷的头部 基团有相似亲水性的氨基酸可包括亮氨酸、 异亮氨酸和缬氨酸; 甘氨酸和丙氨酸; 天冬酰胺和谷氨酰胺; 丝氨酸和苏氨酸; 苯丙氨酸和酪氨酸。  "Similarity" refers to the degree of identical or conservative substitutions of amino acid residues at corresponding positions in the alignment of amino acid sequences. Amino acids used for conservative substitution, for example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; having an uncharged head group is Similar hydrophilic amino acids may include leucine, isoleucine and valine; glycine and alanine; asparagine and glutamine; serine and threonine; phenylalanine and tyrosine.
"反义"是指与特定的 DNA或 RNA序列互补的核苷酸序列。 "反义链"是指与 "有 义链" 互补的核酸链。  "Antisense" refers to a nucleotide sequence that is complementary to a particular DNA or RNA sequence. The "antisense strand" refers to a nucleic acid strand that is complementary to the "sense strand".
"衍生物" 是指 HFP或编码其核酸的化学修饰物。 这种化学修饰物可以是用垸 基、 酰基或氨基替换氢原子。 核酸衍生物可编码保留天然分子的主要生物学特性 的多肽。  "Derivative" refers to HFP or a chemical modification of its nucleic acid. Such a chemical modification may be a substitution of a hydrogen atom with a fluorenyl group, an acyl group or an amino group. Nucleic acid derivatives can encode polypeptides that retain the main biological properties of natural molecules.
"抗体" 是指完整的抗体分子及其片段, 如 Fa、 ?(^') 2及? , 其能特异性 结合肝素结合蛋白 10的抗原决定簇。 "Antibody" refers to a complete antibody molecule and its fragments, such as Fa,? (^ ') 2 and? It can specifically bind to the epitope of heparin-binding protein 10.
"人源化抗体" 是指非抗原结合区域的氨基酸序列被替换变得与人抗体更为 相似, 但仍保留原始结合活性的抗体。  A "humanized antibody" refers to an antibody in which the amino acid sequence of a non-antigen binding region is replaced to become more similar to a human antibody, but still retains the original binding activity.
"分离的" 一词指将物质从它原来的环境 (例如, 若是自然产生的就指其天 然环境) 之中移出。 比如说, 一个自然产生的多核苷酸或多肽存在于活动物中就 是没有被分离出来, 但同样的多核苷酸或多肽同一些或全部在自然系统中与之共 存的物质分开就是分离的。 这样的多核苷酸可能是某一载体的一部分, 也可能这 样的多核苷酸或多肽是某一组合物的一部分。 既然载体或组合物不是它天然环境 的成分, 它们仍然是分离的。 The term "isolated" refers to the removal of a substance from its original environment (for example, its natural environment if it occurs naturally). For example, a naturally-occurring polynucleotide or polypeptide exists in a living animal. It is not isolated, but the same polynucleotide or polypeptide is separated from some or all of the substances that coexist with it in the natural system. Such a polynucleotide may be part of a certain vector, or such a polynucleotide or polypeptide may be part of a certain composition. Since the carrier or composition is not a component of its natural environment, they are still isolated.
如本发明所用, "分离的" 是指物质从其原始环境中分离出来 (如果是天然的 物质, 原始环境即是天然环境)。 如活体细胞内的天然状态下的多聚核苷酸和多肽 是没有分离纯化的, 但同样的多聚核苷酸或多肽如从天然状态中同存在的其他物 质中分开, 则为分离纯化的。  As used herein, "isolated" refers to the separation of a substance from its original environment (if it is a natural substance, the original environment is the natural environment). For example, polynucleotides and polypeptides in a natural state in a living cell are not isolated and purified, but the same polynucleotides or polypeptides are separated and purified if they are separated from other substances existing in the natural state. .
如本文所用, "分离的肝素结合蛋白 10" 是指肝素结合蛋白 10基本上不含 天然与其相关的其它蛋白、 脂类、 糖类或其它物质。 本领域的技术人员能用标 准的蛋白质纯化技术纯化肝素结合蛋白 10。 基本上纯的多肽在非还原聚丙烯酰 胺凝胶上能产生单一的主带。 肝素结合蛋白 1 0 多肽的纯度能用氨基酸序列分 析。  As used herein, "isolated heparin binding protein 10" means that heparin binding protein 10 is substantially free of other proteins, lipids, carbohydrates or other substances with which it is naturally associated. Those skilled in the art can purify heparin binding protein 10 using standard protein purification techniques. Substantially pure polypeptides can produce a single main band on a non-reducing polyacrylamide gel. The purity of the heparin-binding protein 10 peptide can be analyzed by amino acid sequence.
本发明提供了一种新的多肽——肝素结合蛋白 10 , 其基本上是由 SEQ ID NO: 2 所示的氨基酸序列组成的。 本发明的多肽可以是重组多肽、 天然多肽、 合成多肽, 优选重组多肽。 本发明的多肽可以是天然纯化的产物, 或是化学合成的产物, 或 使用重组技术从原核或真核宿主(例如, 细菌、 酵母、 高等植物、 昆虫和哺乳动物 细胞)中产生。 根据重组生产方案所用的宿主, 本发明的多肽可以是糖基化的, 或 可以是非糖基化的。 本发明的多肽还可包括或不包括起始的甲硫氨酸残基。  The present invention provides a new polypeptide, heparin-binding protein 10, which basically consists of the amino acid sequence shown in SEQ ID NO: 2. The polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide, or a synthetic polypeptide, and preferably a recombinant polypeptide. The polypeptides of the present invention can be naturally purified products or chemically synthesized products, or can be produced from prokaryotic or eukaryotic hosts (eg, bacteria, yeast, higher plants, insects, and mammalian cells) using recombinant techniques. Depending on the host used in the recombinant production protocol, the polypeptide of the invention may be glycosylated, or it may be non-glycosylated. Polypeptides of the invention may also include or exclude starting methionine residues.
本发明还包括肝素结合蛋白 10的片段、 衍生物和类似物。 如本发明所用, 术 语 "片段"、 "衍生物" 和 "类似物" 是指基本上保持本发明的肝素结合蛋白 10相 同的生物学功能或活性的多肽。 本发明多肽的片段、 衍生物或类似物可以是: (I ) 这样一种, 其中一个或多个氨基酸残基被保守或非保守氨基酸残基 (优选的是保 守氨基酸残基)取代, 并且取代的氨基酸可以是也可以不是由遗传密码子编码的; 或者 ( I I ) 这样一种, 其中一个或多个氨基酸残基上的某个基团被其它基团取代 包含取代基; 或者 ( Π Ι )这样一种, 其中成熟多肽与另一种化合物 (比如延长多 肽半衰期的化合物, 例如聚乙二醇) 融合; 或者 UV )这样一种, 其中附加的氨 基酸序列融合进成熟多肽而形成的多肽序列 (如前导序列或分泌序列或用来纯化 此多肽的序列或蛋白原序列)。 通过本文的阐述, 这样的片段、 衍生物和类似物被 认为在本领域技术人员的知识范围之内。  The invention also includes fragments, derivatives and analogs of heparin-binding protein 10. As used in the present invention, the terms "fragment", "derivative" and "analog" refer to a polypeptide that substantially maintains the same biological function or activity of the heparin-binding protein 10 of the present invention. The fragment, derivative or analog of the polypeptide of the present invention may be: (I) a kind in which one or more amino acid residues are replaced with conservative or non-conservative amino acid residues (preferably conservative amino acid residues), and the substitution The amino acid may or may not be encoded by a genetic codon; or (II) a type in which a group on one or more amino acid residues is substituted by another group to include a substituent; or (Π Ι) Such a type in which the mature polypeptide is fused with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol); or UV) a type in which the additional amino acid sequence is fused into the mature polypeptide and formed by the polypeptide sequence ( Such as a leader sequence or a secreted sequence or a sequence used to purify this polypeptide or a protein sequence). As set forth herein, such fragments, derivatives and analogs are considered to be within the knowledge of those skilled in the art.
本发明提供了分离的核酸 (多核苷酸), 基本由编码具有 SEQ ID NO: 2 氨基 酸序列的多肽的多核苷酸组成。 本发明的多核苷酸序列包括 SEQ ID NO: 1 的核苷 酸序列。 本发明的多核苷酸 从人胎脑组织的 cDNA文库中发现的。 它包含的多核 苷酸序列全长为 1865个碱基, 其开放读框 343-618编码了 91 个氨基酸。 此多肽 具有肝素结合蛋白的特征序列, 可推断出该肝素结合蛋白 10具有肝素结合蛋白所 代表的结构和功能。 The present invention provides an isolated nucleic acid (polynucleotide), which basically consists of a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2. The polynucleotide sequence of the present invention includes a nucleoside of SEQ ID NO: 1 Acid sequence. The polynucleotide of the present invention is found from a cDNA library of human fetal brain tissue. It contains a polynucleotide sequence of 1865 bases in length and its open reading frames 343-618 encode 91 amino acids. This polypeptide has a characteristic sequence of a heparin-binding protein, and it can be deduced that the heparin-binding protein 10 has the structure and function represented by the heparin-binding protein.
本发明的多核苷酸可以是 DM形式或是 RNA形式。 DNA形式包括 cDNA、 基因 组 DNA或人工合成的 DNA。 DNA可以是单链的或是双链的。 DNA可以是编码链或非 编码链。 编码成熟多肽的编码区序列可以与 SEQ ID N0: 1 所示的编码区序列相同 或者是简并的变异体。 如本发明所用, "简并的变异体" 在本发明中是指编码具有 SEQ ID NO: 2的蛋白质或多肽, 但与 SEQ ID NO: 1所示的编码区序列有差别的核酸 序列。  The polynucleotide of the present invention may be in the form of DM or RNA. DNA forms include cDNA, genomic DNA or synthetic DNA. DNA can be single-stranded or double-stranded. DNA can be coding or non-coding. The coding region sequence encoding a mature polypeptide may be the same as the coding region sequence shown in SEQ ID NO: 1 or a degenerate variant. As used herein, a "degenerate variant" refers to a nucleic acid sequence encoding a protein or polypeptide having SEQ ID NO: 2 but different from the coding region sequence shown in SEQ ID NO: 1 in the present invention.
编码 SEQ ID NO: 2 的成熟多肽的多核苷酸包括: 只有成熟多肽的编码序列; 成熟多肽的编码序列和各种附加编码序列; 成熟多肽的编码序列 (和任选的附加 编码序列) 以及非编码序列。  The polynucleotide encoding the mature polypeptide of SEQ ID NO: 2 includes: only the coding sequence of the mature polypeptide; the coding sequence of the mature polypeptide and various additional coding sequences; the coding sequence of the mature polypeptide (and optional additional coding sequences); Coding sequence.
术语 "编码多肽的多核苷酸" 是指包括编码此多肽的多核苷酸和包括附加编 码和 /或非编码序列的多核苷酸。  The term "polynucleotide encoding a polypeptide" refers to a polynucleotide that includes the polypeptide and a polynucleotide that includes additional coding and / or non-coding sequences.
本发明还涉及上述描述多核苷酸的变异体, 其编码与本发明有相同的氨基酸 序列的多肽或多肽的片断、 类似物和衍生物。 此多核苷酸的变异体可以是天然发 生的等位变异体或非天然发生的变异体。 这些核苷酸变异体包括取代变异体、 缺 失变异体和插入变异体。 如本领域所知的, 等位变异体是一个多核苷酸的替换形 式, 它可能是一个或多个核苷酸的取代、 缺失或插入, 但不会从实质上改变其编 码的多肽的功能。  The invention also relates to variants of the polynucleotides described above, which encode polypeptides or fragments, analogs and derivatives of polypeptides having the same amino acid sequence as the invention. This polynucleotide variant can be a naturally occurring allelic variant or a non-naturally occurring variant. These nucleotide variants include substitution variants, deletion variants, and insertion variants. As known in the art, an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion, or insertion of one or more nucleotides, but does not substantially change the function of the polypeptide it encodes .
本发明还涉及与以上所描述的序列杂交的多核苷酸 (两个序列之间具有至少 50%, 优选具有 70%的相同性)。 本发明特别涉及在严格条件下与本发明所述多核苷 酸可杂交的多核苷酸。 在本发明中, "严格条件" 是指: (1)在较低离子强度和较 高温度下的杂交和洗脱, 如 0. 2xSSC, 0. 1%SDS, 6(TC ;或(2)杂交时加用变性剂, 如 50% (v/v)甲酰胺, 0. 1%小牛血清 /0. l%Fico l l , 42 °C等; 或(3)仅在两条序列之间 的相同性至少在 95%以上,更好是 97%以上时才发生杂交。 并且, 可杂交的多核苷 酸编码的多肽与 SEQ ID NO: 2所示的成熟多肽有相同的生物学功能和活性。  The invention also relates to a polynucleotide that hybridizes to the sequence described above (having at least 50%, preferably 70% identity between the two sequences). The present invention particularly relates to polynucleotides that can hybridize to the polynucleotides of the present invention under stringent conditions. In the present invention, "strict conditions" means: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2xSSC, 0.1% SDS, 6 (TC; or (2) Add denaturants during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Fico ll, 42 ° C, etc .; or (3) only between the two sequences Hybridization occurs only when the identity is at least 95%, and more preferably 97%. Furthermore, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide shown in SEQ ID NO: 2.
本发明还涉及与以上所描述的序列杂交的核酸片段。 如本发明所用, "核酸片 段"的长度至少含 10 个核苷酸, 较好是至少 20-30 个核苷酸, 更好是至少 50-60 个核苷酸, 最好是至少 100个核苷酸以上。 核酸片段也可用于核酸的扩增技术(如 PCR)以确定和 /或分离编码肝素结合蛋白 10的多核苷酸。 本发明中的多肽和多核苷酸优选以分离的形式提供, 更佳地被纯化至均质。 本发明的编码肝素结合蛋白 10 的特异的多核苷酸序列能用多种方法获得。 例如, 用本领域熟知的杂交技术分离多核苷酸。 这些技术包括但不局限于: 1) 用探针与基因组或 cDNA 文库杂交以检出同源的多核苷酸序列, 和 2)表达文库 的抗体筛选以检出具有共同结构特征的克隆的多核苷酸片段。 The invention also relates to nucleic acid fragments that hybridize to the sequences described above. As used in the present invention, a "nucleic acid fragment" contains at least 10 nucleotides in length, preferably at least 20-30 nucleotides, more preferably at least 50-60 nucleotides, and most preferably at least 100 nuclei. Glycylic acid or more. Nucleic acid fragments can also be used in nucleic acid amplification techniques, such as PCR, to identify and / or isolate polynucleotides encoding heparin-binding protein 10. The polypeptides and polynucleotides in the present invention are preferably provided in an isolated form and are more preferably purified to homogeneity. The specific polynucleotide sequence encoding the heparin-binding protein 10 of the present invention can be obtained by various methods. For example, polynucleotides are isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect homologous polynucleotide sequences, and 2 ) antibody screening of expression libraries to detect cloned polynucleosides with common structural characteristics Acid fragments.
本发明的 DNA片段序列也能用下列方法获得: 1)从基因组 DNA分离双链 DNA 序列; 2)化学合成 DNA序列以获得所述多肽的双链 DM。  The DNA fragment sequence of the present invention can also be obtained by the following methods: 1) isolating the double-stranded DNA sequence from the genomic DNA; 2) chemically synthesizing the DNA sequence to obtain the double-stranded DM of the polypeptide.
上述提到的方法中, 分离基因组 DNA 最不常用。 DM序列的直接化学合成 是经常选用的方法。 更经常选用的方法是 cDNA序列的分离。 分离感兴趣的 cDNA 的标准方法是从高表达该基因的供体细胞分离 mRNA 并进行逆转录, 形成质粒 或噬菌体 cDNA文库。 提取 mRNA的方法已有多种成熟的技术, 试剂盒也可从商 业途径获得(Qiagene)。 而构建 cDNA 文库也是通常的方法(Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989)。还可得到商业供应的 cDNA文库,如 Clontech公司的不同 cDNA 文库。 当结合使用聚合酶反应技术时, 即使极少的表达产物也能克隆。  Of the methods mentioned above, genomic DNA isolation is the least commonly used. Direct chemical synthesis of DM sequences is often the method of choice. The more commonly used method is the isolation of cDNA sequences. The standard method for isolating the cDNA of interest is to isolate mRNA from donor cells that overexpress the gene and perform reverse transcription to form a plasmid or phage cDNA library. Various methods have been used to extract mRNA, and kits are also commercially available (Qiagene). The construction of cDNA libraries is also a common method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989). Commercially available cDNA libraries are also available, such as different cDNA libraries from Clontech. When polymerase reaction technology is used in combination, even very small expression products can be cloned.
可用常规方法从这些 cDNA 文库中筛选本发明的基因。 这些方法包括(但不 限于): (l)DM-DNA 或 DNA-RNA 杂交; (2)标志基因功能的出现或丧失; (3)测 定肝素结合蛋白 10 的转录本的水平; (4)通过免疫学技术或测定生物学活性, 来检测基因表达的蛋白产物。 上述方法可单用, 也可多种方法联合应用。  The genes of the present invention can be selected from these cDNA libraries by conventional methods. These methods include (but are not limited to): (1) DM-DNA or DNA-RNA hybridization; (2) the presence or absence of marker gene functions; (3) measuring the level of transcripts of heparin-binding protein 10; (4) passing Immunological techniques or assays for biological activity to detect gene-expressed protein products. The above methods can be used singly or in combination.
在第(1)种方法中, 杂交所用的探针是与本发明的多核苷酸的任何一部分 同源, 其长度至少 10 个核苷酸, 较好是至少 30个核苷酸, 更好是至少 50 个 核苷酸, 最好是至少 100 个核苷酸。 此外, 探针的长度通常在 2000 个核苷酸 之内, 较佳的为 1000 个核苷酸之内。 此处所用的探针通常是在本发明的基因 序列信息的基础上化学合成的 DNA 序列。 本发明的基因本身或者片段当然可以 用作探针。 DNA探针的标记可用放射性同位素, 荧光素或酶(如碱性磷酸酶)等。  In the method (1), the probe used for hybridization is homologous to any part of the polynucleotide of the present invention, and its length is at least 10 nucleotides, preferably at least 30 nucleotides, more preferably At least 50 nucleotides, preferably at least 100 nucleotides. In addition, the length of the probe is usually within 2000 nucleotides, preferably within 1000 nucleotides. The probe used here is usually a DNA sequence chemically synthesized based on the gene sequence information of the present invention. The genes or fragments of the present invention can of course be used as probes. DNA probes can be labeled with radioisotopes, luciferin, or enzymes (such as alkaline phosphatase).
在第(4)种方法中, 检测肝素结合蛋白 10基因表达的蛋白产物可用免疫学 技术如 Western印迹法、 放射免疫沉淀法、 酶联免疫吸附法(ELISA)等。  In the (4) method, immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA) can be used to detect the protein product expressed by the heparin-binding protein 10 gene expression.
应 用 PCR 技术 扩 增 DNA/RNA 的 方 法 (Saiki, et al. Science 1985; 230: 1350-1354)被优选用于获得本发明的基因。 特别是很难从文库中得 到全长的 cDNA时, 可优选使用 RACE法(RACE- cDNA末端快速扩增法),用于 PCR 的引物可根据本文所公开的本发明的多核苷酸序列信息适当地选择, 并可用常 规方法合成。 可用常规方法如通过凝胶电泳分离和纯化扩增的 DNA/RNA片段。 如上所述得到的本发明的基因, 或者各种 DM 片段等的多核苷酸序列可用 常规方法如双脱氧链终止法(Sanger et al. PNAS, 1977, 74: 5463- 5467)测 定。 这类多核苷酸序列测定也可用商业测序试剂盒等。 为了获得全长的 cDNA 序列, 测序需反复进行。 有时需要测定多个克隆的 cDNA 序列, 才能拼接成全 长的 cDNA序列。 A method of amplifying DNA / RNA by PCR (Saiki, et al. Science 1985; 230: 1350-1354) is preferably used to obtain the gene of the present invention. In particular, when it is difficult to obtain a full-length cDNA from a library, the RACE method (RACE-rapid cDNA end rapid amplification method) can be preferably used. The primers for PCR can be appropriately based on the polynucleotide sequence information of the present invention disclosed herein Select and synthesize using conventional methods. The amplified DNA / RNA fragments can be isolated and purified by conventional methods such as by gel electrophoresis. The polynucleotide sequence of the gene of the present invention or various DM fragments and the like obtained as described above can be determined by a conventional method such as dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such polynucleotide sequences can also be determined using commercial sequencing kits and the like. In order to obtain the full-length cDNA sequence, sequencing must be repeated. Sometimes it is necessary to determine the cDNA sequence of multiple clones in order to splice into a full-length cDNA sequence.
本发明也涉及包含本发明的多核苷酸的载体, 以及用本发明的载体或直接 用肝素结合蛋白 10 编码序列经基因工程产生的宿主细胞, 以及经重组技术产 生本发明所述多肽的方法。  The present invention also relates to a vector comprising a polynucleotide of the present invention, and a host cell genetically engineered using the vector of the present invention or directly using a heparin-binding protein 10 coding sequence, and a method for producing a polypeptide of the present invention by recombinant technology.
本发明中, 编码肝素结合蛋白 10 的多核苷酸序列可插入到载体中, 以构 成含有本发明所述多核苷酸的重组载体。 术语 "载体" 指本领域熟知的细菌质 粒、 噬菌体、 酵母质粒、 植物细胞病毒、 哺乳动物细胞病毒如腺病毒、 逆转录 病毒或其它载体。 在本发明中适用的载体包括但不限于: 在细菌中表达的基于 T7 启动子的表达载体(Rosenberg, et al. Gene, 1987, 56: 125); 在哺乳动物 细胞中表达的 pMSXND表达载体(Lee and Nathans, J Bio Chem. 263: 3521, 1988) 和在昆虫细胞中表达的来源于杆状病毒的载体。 总之, 只要能在宿主体内复制 和稳定, 任何质粒和载体都可以用于构建重组表达载体。 表达载体的一个重要 特征是通常含有复制起始点、 启动子、 标记基因和翻译调控元件。  In the present invention, a polynucleotide sequence encoding a heparin-binding protein 10 may be inserted into a vector to form a recombinant vector containing the polynucleotide of the present invention. The term "vector" refers to bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors well known in the art. Vectors suitable for use in the present invention include, but are not limited to: T7 promoter-based expression vectors expressed in bacteria (Rosenberg, et al. Gene, 1987, 56: 125); pMSXND expression vectors expressed in mammalian cells ( Lee and Nathans, J Bio Chem. 263: 3521, 1988) and baculovirus-derived vectors expressed in insect cells. In short, as long as it can be replicated and stabilized in the host, any plasmid and vector can be used to construct a recombinant expression vector. An important feature of expression vectors is that they usually contain origins of replication, promoters, marker genes, and translational regulatory elements.
本领域的技术人员熟知的方法能用于构建含编码肝素结合蛋白 10 的 DNA 序列和合适的转录 /翻译调控元件的表达载体。 这些方法包括体外重组 DNA 技 术、 DNA合成技术、 体内重组技术等(Sambroook, et al. Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989)。 所述的 DNA序列可有效连接到表达载体中的适当启动子上, 以指导 raRNA合成。 这些启动子的代表性例子有: 大肠杆菌的 lac 或 trp 启动子; λ噬菌体的 PL 启动子; 真核启动子包括 CMV 立即早期启动子、 HSV 胸苷激酶启动子、 早期和 晚期 SV40启动子、 反转录病毒的 LTRs 和其它一些已知的可控制基因在原核细 胞或真核细胞或其病毒中表达的启动子。 表达载体还包括翻译起始用的核糖体 结合位点和转录终止子等。 在载体中插入增强子序列将会使其在高等真核细胞 中的转录得到增强。 增强子是 DM表达的顺式作用因子, 通常大约有 10到 300 个碱基对, 作用于启动子以增强基因的转录。 可举的例子包括在复制起始点晚 期一侧的 100 到 270 个碱基对的 SV40增强子、 在复制起始点晚期一侧的多瘤 增强子以及腺病毒增强子等。 Methods known to those skilled in the art can be used to construct expression vectors containing a DNA sequence encoding heparin binding protein 10 and appropriate transcriptional / translational regulatory elements. These methods include in vitro recombinant DNA technology, DNA synthesis technology, and in vivo recombination technology (Sambroook, et al. Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989). The DNA sequence can be operably linked to an appropriate promoter in an expression vector to guide the synthesis of raRNA. Representative examples of these promoters are: the lac or trp promoter of E. coli; the PL promoter of lambda phage; eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, and the early and late SV40 promoters , Retroviral LTRs and other known promoters that control the expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also includes a ribosome binding site and a transcription terminator for translation initiation. Insertion of enhancer sequences into the vector will enhance its transcription in higher eukaryotic cells. Enhancers are cis-acting factors expressed by DM, usually about 10 to 300 base pairs, which act on promoters to enhance gene transcription. Illustrative examples include SV40 enhancers from 100 to 270 base pairs on the late side of the origin of replication, polyoma enhancers on the late side of the origin of replication, and adenovirus enhancers.
此外, 表达载体优选地包含一个或多个选择性标记基因, 以提供用于选择 转化的宿主细胞的表型性状, 如真核细胞培养用的二氢叶酸还原酶、 新霉素抗 性以及绿色荧光蛋白(GFP) , 或用于大肠杆菌的四环素或氨苄青霉素抗性等。 In addition, the expression vector preferably contains one or more selectable marker genes to provide for selection The phenotypic traits of transformed host cells, such as dihydrofolate reductase, neomycin resistance and green fluorescent protein (GFP) for eukaryotic cell culture, or tetracycline or ampicillin resistance for E. coli.
本领域一般技术人员都清楚如何选择适当的载体 /转录调控元件 (如启动 子、 增强子等) 和选择性标记基因。  Those of ordinary skill in the art will know how to select appropriate vector / transcription control elements (such as promoters, enhancers, etc.) and selectable marker genes.
本发明中, 编码肝素结合蛋白 10 的多核苷酸或含有该多核苷酸的重组载 体可转化或转导入宿主细胞, 以构成含有该多核苷酸或重组载体的基因工程化 宿主细胞。 术语 "宿主细胞" 指原核细胞, 如细菌细胞; 或是低等真核细胞, 如酵母细胞; 或是高等真核细胞, 如哺乳动物细胞。 代表性例子有: 大肠杆菌, 链霉菌属; 细菌细胞如鼠伤寒沙门氏菌; 真菌细胞如酵母; 植物细胞; 昆虫细 胞如果蝇 S2或 Sf 9 ; 动物细胞如 CH0、 COS或 Bowe s黑素瘤细胞等。  In the present invention, a polynucleotide encoding a heparin-binding protein 10 or a recombinant vector containing the polynucleotide can be transformed or transduced into a host cell to constitute a genetically engineered host cell containing the polynucleotide or the recombinant vector. The term "host cell" refers to a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples are: E. coli, Streptomyces; bacterial cells such as Salmonella typhimurium; fungal cells such as yeast; plant cells; insect cells such as fly S2 or Sf 9; animal cells such as CH0, COS, or Bowes s melanoma cells, etc. .
用本发明所述的 DNA序列或含有所述 DNA序列的重组载体转化宿主细胞可 用本领域技术人员熟知的常规技术进行。 当宿主为原核生物如大肠杆菌时, 能 吸收 DNA 的感受态细胞可在指数生长期后收获, 用 CaC l 2法处理, 所用的步骤 在本领域众所周知。 可供选择的是用 MgC l 2。 如果需要, 转化也可用电穿孔的 方法进行。 当宿主是真核生物, 可选用如下的 DNA转染方法: 磷酸钙共沉淀法, 或者常规机械方法如显微注射、 电穿孔、 脂质体包装等。 Transformation of a host cell with a DNA sequence described in the present invention or a recombinant vector containing the DNA sequence can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryote such as E. coli, competent cells capable of DNA uptake can be in the exponential growth phase were harvested, treated with CaC l 2 method used in steps well known in the art. The alternative is to use MgC l 2 . If necessary, transformation can also be performed by electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate co-precipitation method, or conventional mechanical methods such as microinjection, electroporation, and liposome packaging.
通过常规的重组 DNA技术, 利用本发明的多核苷酸序列可用来表达或生产 重组的肝素结合蛋白 1 0 (Sc i ence, 1984 ; 224: 1431)。 一般来说有以下步骤: Using conventional recombinant DNA technology, the polynucleotide sequence of the present invention can be used to express or produce a recombinant heparin-binding protein 10 (Scence, 1984; 224: 1431). Generally there are the following steps:
(1)用本发明的编码人 肝素结合蛋白 1 0 的多核苷酸(或变异体), 或用含 有该多核苷酸的重组表达载体转化或转导合适的宿主细胞; (1) using the polynucleotide (or variant) encoding the human heparin binding protein 10 of the present invention, or transforming or transducing a suitable host cell with a recombinant expression vector containing the polynucleotide;
(2)在合适的培养基中培养宿主细胞;  (2) culturing host cells in a suitable medium;
(3)从培养基或细胞中分离、 纯化蛋白质。  (3) Isolate and purify protein from culture medium or cells.
在步骤 (2 ) 中, 根据所用的宿主细胞, 培养中所用的培养基可选自各种 常规培养基。 在适于宿主细胞生长的条件下进行培养。 当宿主细胞生长到适当 的细胞密度后, 用合适的方法(如温度转换或化学诱导)诱导选择的启动子, 将 细胞再培养一段时间。  In step (2), depending on the host cell used, the medium used in the culture may be selected from various conventional mediums. Culture is performed under conditions suitable for host cell growth. After the host cells have grown to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
在步骤 ( 3 ) 中, 重组多肽可包被于细胞内、 或在细胞膜上表达、 或分泌 到细胞外。 如果需要, 可利用其物理的、 化学的和其它特性通过各种分离方法 分离和纯化重组的蛋白。 这些方法是本领域技术人员所熟知的。 这些方法包括 但并不限于: 常规的复性处理、 蛋白沉淀剂处理(盐析方法)、 离心、 渗透破菌、 超声波处理、 超离心、 分子筛层析(凝胶过滤)、 吸附层析、 离子交换层析、 高 效液相层析(HPLC)和其它各种液相层析技术及这些方法的结合。 本发明的多肽以及该 肽的拮抗剂、 激动剂和抑制剂可直接用于疾病治 疗, 例如, 可治疗恶性肿瘤、 贤上腺缺乏症、 皮肤病、 各类炎症、 HIV 感染和免 疫性疾病等。 In step (3), the recombinant polypeptide may be coated in a cell, expressed on a cell membrane, or secreted outside the cell. If desired, recombinant proteins can be isolated and purified by various separation methods using their physical, chemical, and other properties. These methods are well known to those skilled in the art. These methods include, but are not limited to: conventional renaturation treatment, protein precipitant treatment (salting out method), centrifugation, osmotic disruption, ultrasonic treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion Exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods. The polypeptide of the present invention and the antagonists, agonists and inhibitors of the peptide can be directly used in the treatment of diseases, for example, it can treat malignant tumors, adrenal deficiency, skin diseases, various inflammations, HIV infections and immune diseases, etc. .
PKN/MK 肝素结合蛋白是一类细胞外肝素结合蛋白, 这些蛋白在生物体内涉及 各种细胞的生长与分化调控过程, 这类蛋白构成了一新的肝素结合蛋白家族, 该 家族的成员均为一些生长调节因子 [Tsutsui J., et a l. , 1991]。 PKN/M 肝素结 合蛋白家族特异的保守序列是形成其活性 mot if 所必需。  PKN / MK heparin-binding proteins are a class of extracellular heparin-binding proteins. These proteins are involved in the regulation of the growth and differentiation of various cells in the body. These proteins constitute a new family of heparin-binding proteins. Some growth regulators [Tsutsui J., et al., 1991]. The PKN / M heparin-binding protein family-specific conserved sequence is required to form its active mot if.
由此可见, 特异的 PKN/MK 肝素结合蛋白 mot if 的表达异常, 将致使本发明 的含此 mot if 的多肽的功能异常, 从而导致细胞分化、 增殖、 机体生长调控异常, 并产生相关的疾病如肿瘤、 胚胎发育紊乱、 生长发育障碍等。 由于肝素在凝血机 制中具有非常重要作用, 肝素结合蛋白与肝素的结合可致凝血机制异常, 并产生 相关的疾病如凝血障碍性疾病。  It can be seen that abnormal expression of the specific PKN / MK heparin-binding protein mot if will cause abnormal function of the polypeptide containing the mot if of the present invention, resulting in abnormal cell differentiation, proliferation, abnormal growth regulation of the body, and related diseases. Such as tumors, embryonic development disorders, growth and development disorders. Because heparin plays a very important role in the coagulation mechanism, the combination of heparin-binding protein and heparin can cause abnormal coagulation mechanisms and produce related diseases such as coagulopathy.
由此可见, 本发明的肝素结合蛋白 10 的表达异常将产生各种疾病尤其是凝 血障碍性疾病、 胚胎发育紊乱、 生长发育障碍, 这些疾病包括但不限于:  It can be seen that the abnormal expression of heparin-binding protein 10 of the present invention will produce various diseases, especially coagulopathy, embryonic developmental disorders, and growth and development disorders. These diseases include, but are not limited to:
凝血障碍性疾病: 凝血因子缺乏症, 血友病 A, 血友病 B, 遗传性出血性毛细 血管扩张症, 过敏性紫癜, 单纯性紫癜, 老年性紫癜, 特发性血小板减少性紫癜, 再生障碍性贫血, 播散性血管内凝血, 心肌梗塞, 脑血栓, 肺血栓  Coagulation disorders: clotting factor deficiency, hemophilia A, hemophilia B, hereditary bleeding telangiectasia, allergic purpura, simple purpura, senile purpura, idiopathic thrombocytopenic purpura, regeneration Obstructive anemia, disseminated intravascular coagulation, myocardial infarction, cerebral thrombosis, pulmonary thrombosis
胚胎发育紊乱症: 先天性流产、 腭裂、 肢体缺如、 肢体分化障碍、 透明膜病、 肺膨胀不全、 多囊肾、 双输尿管、 隐睾、 先天性腹股沟疝、 双子宫、 阴道闭锁、 尿道下裂、 两性畸形、 房间隔缺损、 室间隔缺损、 肺动脉狭窄、 动脉导管未闭、 神经管缺陷、 先天性脑积水、 虹膜缺损、 先天性白内障、 先天性青光眼或白内障、 先天性耳聋  Embryonic disorders: congenital abortion, cleft palate, limb loss, limb differentiation disorder, hyaline membrane disease, atelectasis, polycystic kidney, double ureter, cryptorchidism, congenital inguinal hernia, double uterus, vaginal atresia, suburethral Fissure, hermaphroditism, atrial septal defect, ventricular septal defect, pulmonary stenosis, arterial duct occlusion, neural tube defect, congenital hydrocephalus, iris defect, congenital cataract, congenital glaucoma or cataract, congenital deafness
生长发育障碍性疾病: 精神发育迟缓, 脑性瘫痪, 脑发育障碍, 智力障碍, 家族性脑神经核发育不全综合症, 斜视, 皮肤、 脂肪和肌肉发育不良性疾病如先 天性皮肤松弛症、 早老症、 先天性角化不良, 各种代谢缺陷病如各种氨基酸代谢 缺陷症, 呆小症, 侏儒症, 性发育迟缓症  Growth and development disorders: mental retardation, cerebral palsy, brain development disorders, mental retardation, familial cerebral nucleus dysplasia syndrome, strabismus, skin, fat and muscular dysplasia such as congenital skin laxity, premature aging Disease, congenital keratosis, various metabolic defects such as various amino acid metabolic defects, stunting, dwarfism, sexual retardation
各种组织的肿瘤: 胃癌、 肝癌、 肺癌、 食管癌、 乳腺癌、 白血病、 淋巴瘤、 甲状腺肿瘤、 子宫肌瘤、 成神经细胞瘤、 星形细胞瘤、 室管膜瘤、 胶质细胞瘤、 结肠癌、 黑色素瘤、 肾上腺癌、 膀胱癌、 骨癌、 骨肉瘤、 骨髓瘤、 骨髓癌、 脑癌、 子宫癌、 子宫内膜癌、 胆囊癌、 结肠癌、 胸腺肿瘤、 鼻腔及鼻窦肿瘤、 鼻咽癌、 喉癌、 气管肿瘤、 纤维瘤、 纤维肉瘤、 脂肪瘤、 脂肪肉瘤、 平滑肌瘤  Tumors of various tissues: gastric cancer, liver cancer, lung cancer, esophageal cancer, breast cancer, leukemia, lymphoma, thyroid tumor, uterine fibroids, neuroblastoma, astrocytoma, ependymoma, glioblastoma, Colon cancer, melanoma, adrenal cancer, bladder cancer, bone cancer, osteosarcoma, myeloma, bone marrow cancer, brain cancer, uterine cancer, endometrial cancer, gallbladder cancer, colon cancer, thymic tumor, nasal cavity and sinus tumor, nose Pharyngeal cancer, Laryngeal cancer, Tracheal tumor, Fibroma, Fibrosarcoma, Lipoma, Liposarcoma, Leiomyoma
本发明的肝素结合蛋白 10 的表达异常还将产生某些遗传性, 血液性疾病及 免疫系统疾病等。 The abnormal expression of heparin-binding protein 10 of the present invention will also produce certain hereditary, hematological diseases and Diseases of the immune system, etc.
本发明的多肽以及该多肽的拮抗剂、 激动剂和抑制剂可直接用于疾病治 疗, 例如, 可治疗各种疾病尤其是凝血障碍性疾病、 肿瘤、 胚胎发育紊乱、 生长 发育障碍, 某些遗传性, 血液性疾病及免疫系统疾病等。  The polypeptide of the present invention and the antagonists, agonists and inhibitors of the polypeptide can be directly used in the treatment of diseases, for example, it can treat various diseases, especially coagulopathy, tumors, embryonic development disorders, growth and development disorders, and some inheritances. Sexual, hematological and immune system diseases.
本发明也提供了筛选化合物以鉴定提高(激动剂)或阻遏(拮抗剂)肝素结合 蛋白 10的药剂的方法。 激动剂提高肝素结合蛋白 10刺激细胞增殖等生物功能, 而拮抗剂阻止和治疗与细胞过度增殖有关的紊乱如各种癌症。 例如, 能在药物 的存在下, 将哺乳动物细胞或表达肝素结合蛋白 10 的膜制剂与标记的肝素结 合蛋白 10—起培养。 然后测定药物提高或阻遏此相互作用的能力。  The invention also provides methods for screening compounds to identify agents that increase (agonist) or suppress (antagonist) heparin binding protein 10. Agonists enhance biological functions such as heparin-binding protein 10 to stimulate cell proliferation, while antagonists prevent and treat disorders related to excessive cell proliferation, such as various cancers. For example, mammalian cells or membrane preparations expressing heparin binding protein 10 can be cultured together with labeled heparin binding protein 10 in the presence of drugs. The ability of the drug to increase or block this interaction is then determined.
肝素结合蛋白 10 的拮抗剂包括筛选出的抗体、 化合物、 受体缺失物和类 似物等。 肝素结合蛋白 10的拮抗剂可以与肝素结合蛋白 10结合并消除其功能, 或是抑制该多肽的产生, 或是与该多肽的活性位点结合使该多肽不能发挥生物 学功能。  Antagonists of heparin-binding protein 10 include antibodies, compounds, receptor deletions, and analogs that have been screened. An antagonist of heparin-binding protein 10 can bind to and eliminate the function of heparin-binding protein 10, or inhibit the production of the polypeptide, or bind to the active site of the polypeptide so that the polypeptide cannot perform a biological function.
在筛选作为拮抗剂的化合物时, 可以将肝素结合蛋白 10 加入生物分析测 定中, 通过测定化合物对肝素结合蛋白 10 和其受体之间相互作用的影响来确 定化合物是否是拮抗剂。 用上述筛选化合物的同样方法, 可以筛选出起拮抗剂 作用的受体缺失物和类似物。 能与肝素结合蛋白 10 结合的多肽分子可通过筛 选由各种可能组合的氨基酸结合于固相物组成的随机多肽库而获得。 筛选时, 一般应对肝素结合蛋白 10分子进行标记。  When screening compounds as antagonists, heparin-binding protein 10 can be added to the bioanalytical assay to determine whether the compound is an antagonist by measuring the effect of the compound on the interaction between heparin-binding protein 10 and its receptor. Receptor deletions and analogs that act as antagonists can be screened in the same manner as described above for screening compounds. Polypeptide molecules capable of binding to heparin-binding protein 10 can be obtained by screening a random peptide library composed of various possible combinations of amino acids bound to a solid phase. When screening, 10 molecules of heparin-binding protein should generally be labeled.
本发明提供了用多肽, 及其片段、 衍生物、 类似物或它们的细胞作为抗原 以生产抗体的方法。 这些抗体可以是多克隆抗体或单克隆抗体。 本发明还提供 了针对肝素结合蛋白 10 抗原决定簇的抗体。 这些抗体包括(但不限于): 多克 隆抗体、 单克隆抗体、 嵌合抗体、 单链抗体、 Fab 片段和 Fab 表达文库产生的 片段。  The present invention provides a method for producing antibodies using polypeptides, and fragments, derivatives, analogs or cells thereof as antigens. These antibodies can be polyclonal or monoclonal antibodies. The invention also provides antibodies against heparin-binding protein 10 epitopes. These antibodies include (but are not limited to): Doklon antibodies, monoclonal antibodies, chimeric antibodies, single-chain antibodies, Fab fragments, and fragments from Fab expression libraries.
多克隆抗体的生产可用肝素结合蛋白 10 直接注射免疫动物 (如家兔, 小 鼠, 大鼠等) 的方法得到, 多种佐剂可用于增强免疫反应, 包括但不限于弗氏 佐剂等。 制备肝素结合蛋白 10 的单克隆抗体的技术包括但不限于杂交瘤技术 (Kohler and Milstein. Nature, 1975, 256: 495-497) , 三瘤技术, 人 Β-细胞 杂交瘤技术, EBV-杂交瘤技术等。 将人恒定区和非人源的可变区结合的嵌合抗 体可用已有的技术生产(Morrison et al , PNAS, 1985, 81: 6851)。 而已有的生 产单链抗体的技术(U. S. Pat No.4946778)也可用于生产抗肝素结合蛋白 10 的 单链抗体。 抗肝素结合蛋白 10 的抗体可用于免疫组织化学技术中, 检测活检标本中 的肝素结合蛋白 10。 Polyclonal antibodies can be produced by injecting heparin-binding protein 10 directly into immunized animals (such as rabbits, mice, rats, etc.). A variety of adjuvants can be used to enhance the immune response, including but not limited to Freund's adjuvant. Techniques for preparing monoclonal antibodies to heparin-binding protein 10 include, but are not limited to, hybridoma technology (Kohler and Milstein. Nature, 1975, 256: 495-497), triple tumor technology, human beta-cell hybridoma technology, and EBV-hybridoma Technology, etc. Chimeric antibodies that bind human constant regions to non-human-derived variable regions can be produced using existing techniques (Morrison et al, PNAS, 1985, 81: 6851). The existing technology for producing single chain antibodies (US Pat No. 4946778) can also be used to produce single chain antibodies against heparin-binding protein 10. Anti-heparin-binding protein 10 antibodies can be used in immunohistochemical techniques to detect heparin-binding protein 10 in biopsy specimens.
与肝素结合蛋白 10 结合的单克隆抗体也可用放射性同位素标记, 注入体 内可跟踪其位置和分布。 这种放射性标记的抗体可作为一种非创伤性诊断方法 用于肿瘤细胞的定位和判断是否有转移。  Monoclonal antibodies that bind to heparin-binding protein 10 can also be labeled with radioisotopes and injected into the body to track their location and distribution. This radiolabeled antibody can be used as a non-invasive diagnostic method to locate tumor cells and determine whether there is metastasis.
抗体还可用于设计针对体内某一特殊部位的免疫毒素。 如肝素结合蛋白 1 0 高亲和性的单克隆抗体可与细菌或植物毒素(如白喉毒素, 蓖麻蛋白, 红豆碱 等)共价结合。 一种通常的方法是用巯基交联剂如 SPDP , 攻击抗体的氨基, 通 过二硫键的交换, 将毒素结合于抗体上, 这种杂交抗体可用于杀灭肝素结合蛋 白 1 0阳性的细胞。  Antibodies can also be used to design immunotoxins that target a particular part of the body. For example, a high-affinity monoclonal antibody of heparin-binding protein 10 can covalently bind to bacterial or plant toxins (such as diphtheria toxin, ricin, ormosine, etc.). A common method is to attack the amino group of an antibody with a thiol cross-linking agent such as SPDP and bind the toxin to the antibody through the exchange of disulfide bonds. This hybrid antibody can be used to kill heparin-binding protein 10-positive cells.
本发明中的抗体可用于治疗或预防与肝素结合蛋白 1 0 相关的疾病。 给予 适当剂量的抗体可以刺激或阻断肝素结合蛋白 10的产生或活性。  The antibodies in the present invention can be used to treat or prevent diseases related to heparin-binding protein 1 0. Administration of an appropriate dose of antibody can stimulate or block the production or activity of heparin-binding protein 10.
本发明还涉及定量和定位检测肝素结合蛋白 1 0 水平的诊断试验方法。 这 些试验是本领域所熟知的, 且包括 FISH 测定和放射免疫测定。 试验中所检测 的肝素结合蛋白 10水平, 可以用作解释肝素结合蛋白 10在各种疾病中的重要 性和用于诊断肝素结合蛋白 1 0起作用的疾病。  The invention also relates to a diagnostic test method for quantitatively and locally detecting the level of heparin-binding protein 10. These tests are well known in the art and include FISH assays and radioimmunoassays. The levels of heparin-binding protein 10 detected in the test can be used to explain the importance of heparin-binding protein 10 in various diseases and to diagnose diseases in which heparin-binding protein 10 plays a role.
本发明的多肽还可用作肽谱分析, 例如, 多肽可用物理的、 化学或酶进行 特异性切割, 并进行一维或二维或三维的凝胶电泳分析,更好的是进行质谱分 析。  The polypeptide of the present invention can also be used for peptide mapping analysis. For example, the polypeptide can be specifically cleaved by physical, chemical or enzymatic analysis, and subjected to one-dimensional or two-dimensional or three-dimensional gel electrophoresis analysis, and more preferably mass spectrometry analysis.
编码肝素结合蛋白 1 0 的多核苷酸也可用于多种治疗目的。 基因治疗技术 可用于治疗由于肝素结合蛋白 1 0 的无表达或异常 /无活性表达所致的细胞增 殖、 发育或代谢异常。 重组的基因治疗载体(如病毒载体)可设计用于表达变异 的肝素结合蛋白 1 0 , 以抑制内源性的肝素结合蛋白 1 0 活性。 例如, 一种变异 的肝素结合蛋白 10可以是缩短的、 缺失了信号传导功能域的肝素结合蛋白 1 0 , 虽可与下游的底物结合, 但缺乏信号传导活性。 因此重组的基因治疗载体可用 于治疗肝素结合蛋白 1 0 表达或活性异常所致的疾病。 来源于病毒的表达载体 如逆转录病毒、 腺病毒、 腺病毒相关病毒、 单纯疱疹病毒、 细小病毒等可用于 将编码肝素结合蛋白 10 的多核苷酸转移至细胞内。 构建携带编码肝素结合蛋 白 1 0 的多核苷酸的重组病毒载体的方法可见于已有文献(Sambrook,e t a l . )。 另外重组编码肝素结合蛋白 1 0的多核苷酸可包装到脂质体中转移至细胞内。  Polynucleotides encoding heparin-binding protein 10 can also be used for a variety of therapeutic purposes. Gene therapy technology can be used to treat abnormal cell proliferation, development or metabolism caused by the non-expression or abnormal / inactive expression of heparin-binding protein 10. Recombinant gene therapy vectors (such as viral vectors) can be designed to express variant heparin-binding protein 10 to inhibit endogenous heparin-binding protein 10 activity. For example, a variant heparin-binding protein 10 may be a shortened heparin-binding protein 10 lacking a signaling domain, and although it can bind to downstream substrates, it lacks signaling activity. Therefore, recombinant gene therapy vectors can be used to treat diseases caused by abnormal expression or activity of heparin-binding protein 10. Virus-derived expression vectors such as retrovirus, adenovirus, adenovirus-associated virus, herpes simplex virus, parvovirus, etc. can be used to transfer a polynucleotide encoding a heparin-binding protein 10 into a cell. A method for constructing a recombinant viral vector carrying a polynucleotide encoding a heparin-binding protein 10 can be found in the existing literature (Sambrook, et al.). In addition, a recombinant polynucleotide encoding heparin-binding protein 10 can be packaged into liposomes and transferred into cells.
多核苷酸导入组织或细胞内的方法包括: 将多核苷酸直接注入到体内组织 中; 或在体外通过载体(如病毒、 噬菌体或质粒等)先将多核苷酸导入细胞中, 再将细胞移植到体内等。 Methods for introducing a polynucleotide into a tissue or cell include: injecting the polynucleotide directly into a tissue in vivo; or introducing the polynucleotide into a cell through a vector (such as a virus, phage, or plasmid) in vitro, The cells are then transplanted into the body and the like.
抑制肝素结合蛋白 10 mRNA的寡核苷酸(包括反义 RNA和 DM)以及核酶也 在本发明的范围之内。 核酶是一种能特异性分解特定 RNA的酶样 RNA分子, 其 作用机制是核酶分子与互补的靶 RNA 特异性杂交后进行核酸内切作用。 反义的 NA和 DNA及核酶可用已有的任何 RNA或 DM合成技术获得, 如固相磷酸酰胺 化学合成法合成寡核苷酸的技术已广泛应用。 反义 RNA 分子可通过编码该 RNA 的 DM序列在体外或体内转录获得。 这种 DNA序列已整合到载体的 RNA聚合酶 启动子的下游。 为了增加核酸分子的稳定性, 可用多种方法对其进行修饰, 如 增加两侧的序列长度, 核糖核苷之间的连接应用磷酸硫酯键或肽键而非磷酸二 酯键。  Oligonucleotides (including antisense RNA and DM) and ribozymes that inhibit heparin-binding protein 10 mRNA are also within the scope of the present invention. A ribozyme is an enzyme-like RNA molecule that specifically decomposes specific RNA. Its mechanism of action is that the ribozyme molecule specifically hybridizes with a complementary target RNA for endonucleation. Antisense NA, DNA, and ribozymes can be obtained using any existing RNA or DM synthesis techniques, such as solid-phase phosphate amide chemical synthesis to synthesize oligonucleotides. Antisense RNA molecules can be obtained by in vitro or in vivo transcription of DM sequences encoding the RNA. This DNA sequence has been integrated downstream of the RNA polymerase promoter of the vector. In order to increase the stability of the nucleic acid molecule, it can be modified in a variety of ways, such as increasing the sequence length on both sides, and the linkage between ribonucleosides using phosphorothioate or peptide bonds instead of phosphodiester bonds.
编码肝素结合蛋白 10的多核苷酸可用于与肝素结合蛋白 10的相关疾病的 诊断。 编码肝素结合蛋白 10的多核苷酸可用于检测肝素结合蛋白 10 的表达与 否或在疾病状态下肝素结合蛋白 10的异常表达。如编码肝素结合蛋白 10的 DNA 序列可用于对活检标本进行杂交以判断肝素结合蛋白 10 的表达状况。 杂交技 术包括 Southern 印迹法、 Northern 印迹法、 原位杂交等。 这些技术方法都是 公开的成熟技术, 相关的试剂盒都可从商业途径得到。 本发明的多核苷酸的一 部分或全部可作为探针固定在微阵列(Microarray)或 DNA 芯片(又称为 "基因 芯片" )上, 用于分析组织中基因的差异表达分析和基因诊断。 用肝素结合蛋 白 10 特异的引物进行 RNA -聚合酶链反应(RT-PCR)体外扩增也可检测肝素结合 蛋白 10的转录产物。  The polynucleotide encoding heparin-binding protein 10 can be used for the diagnosis of diseases related to heparin-binding protein 10. The polynucleotide encoding heparin-binding protein 10 can be used to detect the expression of heparin-binding protein 10 or the abnormal expression of heparin-binding protein 10 in a disease state. For example, the DNA sequence encoding heparin-binding protein 10 can be used to hybridize biopsy specimens to determine the expression of heparin-binding protein 10. Hybridization techniques include Southern blotting, Northern blotting, and in situ hybridization. These techniques and methods are publicly available and mature, and related kits are commercially available. A part or all of the polynucleotide of the present invention can be used as a probe to be fixed on a microarray (Microarray) or a DNA chip (also referred to as a "gene chip") for analyzing differential expression analysis and gene diagnosis of genes in tissues. Heparin-binding protein 10 specific primers can also be used to detect the transcription products of heparin-binding protein 10 by RNA-polymerase chain reaction (RT-PCR) in vitro amplification.
检测肝素结合蛋白 10基因的突变也可用于诊断肝素结合蛋白 10相关的疾 病。 肝素结合蛋白 10突变的形式包括与正常野生型肝素结合蛋白 10 DNA序列 相比的点突变、易位、缺失、重组和其它任何异常等。可用已有的技术如 Southern 印迹法、 DNA 序列分析、 PCR 和原位杂交检测突变。 另外, 突变有可能影响蛋 白的表达, 因此用 Northern印迹法、 Western印迹法可间接判断基因有无突变。  Detection of mutations in the heparin-binding protein 10 gene can also be used to diagnose heparin-binding protein 10-related diseases. Heparin-binding protein 10 mutations include point mutations, translocations, deletions, recombinations, and any other abnormalities compared to the normal wild-type heparin-binding protein 10 DNA sequence. Mutations can be detected using existing techniques such as Southern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, mutations may affect protein expression, so Northern blotting and Western blotting can be used to indirectly determine whether a gene is mutated.
本发明的序列对染色体鉴定也是有价值的。 该序列会特异性地针对某条人 染色体具体位置并且可以与其杂交。 目前, 需要鉴定染色体上的各基因的具体 位点。 现在, 只有很少的基于实际序列数据(重复多态性)的染色体标记物可用 于标记染色体位置。 根据本发明, 为了将这些序列与疾病相关基因相关联, 其 重要的第一步就是将这些 DNA序列定位于染色体上。  The sequences of the invention are also valuable for chromosome identification. This sequence will specifically target a specific position on a human chromosome and can hybridize to it. Currently, specific sites for each gene on the chromosome need to be identified. Currently, only a few chromosome markers based on actual sequence data (repeating polymorphisms) are available for marking chromosome positions. According to the present invention, in order to associate these sequences with disease-related genes, an important first step is to locate these DNA sequences on a chromosome.
简而言之, 根据 cDNA制备 PCR引物(优选 15-35bp) , 可以将序列定位于染色 有那些含有相应于引物的人基因的杂合细胞会产生扩增的片段。 In short, PCR primers (preferably 15-35bp) are prepared based on the cDNA, which can be used to position the sequence for staining. Heterozygous cells that contain human genes corresponding to the primers produce amplified fragments.
体细胞杂合细胞的 PCR 位法, 是将 DNA定位到具体染色体的快捷方法。 使 用本发明的寡核苷酸引物, 通过类似方法, 可利用一组来自特定染色体的片段 或大量基因组克隆而实现亚定位。 可用于染色体定位的其它类似策略包括原位 杂交、 用标记的流式分选的染色体预筛选和杂交预选, 从而构建染色体特异的 cDNA库。  The PCR bit method for somatic hybrid cells is a quick way to locate DNA to a specific chromosome. Using the oligonucleotide primers of the present invention, in a similar manner, a set of fragments from a specific chromosome or a large number of genomic clones can be used to achieve sublocalization. Other similar strategies that can be used for chromosomal localization include in situ hybridization, chromosome pre-screening with labeled flow sorting, and pre-selection of hybridization to construct chromosome-specific cDNA libraries.
将 cDNA克隆与中期染色体进行荧光原位杂交(FISH) , 可以在一个步骤中精 确地进行染色体定位。此技术的综述参见 Verma等, Human Chromosomes: a Manua l of Bas i c Techniques, Pergamon Pres s, New York (1988)。  Fluorescent in situ hybridization (FISH) of cDNA clones with metaphase chromosomes allows precise chromosomal localization in one step. For a review of this technique, see Verma et al., Human Chromosomes: a Manua l of Basic Techniques, Pergamon Pres s, New York (1988).
一旦序列被定位到准确的染色体位置, 此序列在染色体上的物理位置就可 以与基因图数据相关联。 这些数据可见于 V. Mckus i ck,Mendel ian Inher i tance in Man (可通过与 Johns Hopk ins Uni vers i ty Wel ch Med i ca l Li brary联机获 得)。 然后可通过连锁分析, 确定基因与业已定位到染色体区域上的疾病之间 的关系。  Once the sequence is located at the exact chromosomal location, the physical location of the sequence on the chromosome can be correlated with the genetic map data. These data can be found in V. Mckus i ck, Mendelian ian Inheritance in Man (available online with Johns Hopk ins University Wet ch Med i ca l Li brary). Linkage analysis can then be used to determine the relationship between genes and diseases that have been mapped to chromosomal regions.
接着, 需要测定患病和未患病个体间的 cDNA或基因组序列差异。 如果在一 些或所有的患病个体中观察到某突变, 而该突变在任何正常个体中未观察到, 则该突变可能是疾病的病因。 比较患病和未患病个体, 通常涉及首先寻找染色 体中结构的变化, 如从染色体水平可见的或用基于 cDNA序列的 PCR可检测的缺 失或易位。 根据目前的物理作图和基因定位技术的分辨能力, 被精确定位至与 疾病有关的染色体区域的 cDNA, 可以是 50至 500个潜在致病基因间之一种(假定 1兆碱基作图分辨能力和每 20kb对应于一个基因)。  Next, the difference in cDNA or genomic sequence between the affected and unaffected individuals needs to be determined. If a mutation is observed in some or all diseased individuals and the mutation is not observed in any normal individuals, the mutation may be the cause of the disease. Comparing affected and unaffected individuals usually involves first looking for structural changes in chromosomes, such as deletions or translocations that are visible at the chromosomal level or detectable with cDNA sequence-based PCR. According to the resolution capabilities of current physical mapping and gene mapping technology, the cDNA accurately mapped to the chromosomal region associated with the disease can be one of 50 to 500 potentially pathogenic genes (assuming 1 megabase mapping resolution) Capacity and each 20kb corresponds to a gene).
可以将本发明的多肽、 多核苷酸及其模拟物、 激动剂、 拮抗剂和抑制剂与 合适的药物载体组合后使用。 这些载体可以是水、 葡萄糖、 乙醇、 盐类、 缓冲 液、 甘油以及它们的组合。 组合物包含安全有效量的多肽或拮抗剂以及不影响 药物效果的载体和赋形剂。 这些组合物可以作为药物用于疾病治疗。  The polypeptides, polynucleotides and mimetics, agonists, antagonists and inhibitors of the present invention can be used in combination with a suitable pharmaceutical carrier. These carriers can be water, glucose, ethanol, salts, buffers, glycerol, and combinations thereof. The composition comprises a safe and effective amount of the polypeptide or antagonist, and carriers and excipients which do not affect the effect of the drug. These compositions can be used as drugs for the treatment of diseases.
本发明还提供含有一种或多种容器的药盒或试剂盒, 容器中装有一种或多 种本发明的药用组合物成分。 与这些容器一起, 可以有由制造、 使用或销售药 品或生物制品的政府管理机构所给出的指示性提示, 该提示反映出生产、 使用 或销售的政府管理机构许可其在人体上施用。 此外, 本发明的多肽可以与其它 的治疗化合物结合使用。  The invention also provides a kit or kit containing one or more containers containing one or more ingredients of the pharmaceutical composition of the invention. Along with these containers, there may be instructional instructions given by government agencies that manufacture, use, or sell pharmaceuticals or biological products, which prompts permission for administration on the human body by government agencies that produce, use, or sell. In addition, the polypeptides of the invention can be used in combination with other therapeutic compounds.
药物组合物可以以方便的方式给药, 如通过局部、 静脉内、 腹膜内、 肌内、 皮下、 鼻内或皮内的给药途径。 肝素结合蛋白 10 以有效地治疗和 /或预防具体 的适应症的量来给药。 施用于患者的肝素结合蛋白 10 的量和剂量范围将取决 于许多因素, 如给药方式、 待治疗者的健康条件和诊断医生的判断。 The pharmaceutical composition can be administered in a convenient manner, such as by a topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal route of administration. Heparin-binding protein 10 to effectively treat and / or prevent specific The amount of indication to be administered. The amount and range of heparin binding protein 10 administered to a patient will depend on many factors, such as the mode of administration, the health conditions of the person to be treated, and the judgment of the diagnostician.
实施例  Examples
下面结合具体实施例, 进一步阐述本发明。 应理解, 这些实施例仅用于说明 本发明而不用于限制本发明的范围。 下列实施例中未注明具体条件的实验方法, 通常按照常规条件如 Sambrook 等人, 分子克隆: 实验室手册(New York: Cold Spring Harbor Laboratory Press, 1989)中所述的条件, 或按照制造厂商所建议 的条件。  The present invention is further described below with reference to specific embodiments. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention. In the following examples, the experimental methods without specific conditions are generally performed according to conventional conditions such as Sambrook et al., Molecular Cloning: The conditions described in the laboratory manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer Suggested conditions.
实施例 1 肝素结合蛋白 10的克隆  Example 1 Cloning of heparin-binding protein 10
用异硫氰酸胍 /酴 /氯仿一步法提取人胎脑总 RNA。 用 Quik mRNA Isolation Kit (Qiegene 公司产品) 从总 RNA中分离 poly (A) mRNA。 2ug poly (A) mRNA经逆转录 形成 cDNA。用 Smart cDM克隆试剂盒(购自 Clontech )将 cDNA片段定向插入到 pBSK (+) 载体(Clontech公司产品)的多克隆位点上, 转化 DH5a, 细菌形成 cDNA文库。 用 Dye terminate cycle reaction sequencing kit (Perkin—Elmer公司产品) 和 ABI 377 自动测序仪(Perkin- Elmer公司)测定所有克隆的 5'和 3'末端的序列。将测定的 cDNA 序列与已有的公共 D 序列数据库 (Genebank)进行比较, 结果发现其中一个克隆 0660D02的 cDNA序列为新的 D 。 通过合成一系列引物对该克隆所含的插入 cDNA片 段进行双向测定。结果表明, 0660D02克隆所含的全长 cDNA为 1865bp (如 Seq IDN0: 1 所示) , 从第 343bp至 618bp有一个 276p的开放阅读框架 ( 0RF ) , 编码一个新的蛋 白质 (如 Seq ID NO: 2所示) 。 我们将此克隆命名为 pBS-0660D02, 编码的蛋白质 命名为肝素结合蛋白 10。 实施例 2 cDNA 克隆的结构域分析  Total human fetal brain RNA was extracted with guanidine isothiocyanate / amidine / chloroform in one step. Poly (A) mRNA was isolated from total RNA using the Quik mRNA Isolation Kit (Qiegene). 2ug poly (A) mRNA is reverse transcribed to form cDNA. A Smart cDM cloning kit (purchased from Clontech) was used to insert the cDNA fragment into the multicloning site of the pBSK (+) vector (Clontech) to transform DH5a. The bacteria formed a cDNA library. Dye terminate cycle reaction sequencing kit (Perkin-Elmer) and ABI 377 automatic sequencer (Perkin-Elmer) were used to determine the sequences at the 5 'and 3' ends of all clones. The determined cDNA sequence was compared with the existing public D sequence database (Genebank), and it was found that the cDNA sequence of one of the clones 0660D02 was the new D. The inserted cDNA fragments contained in this clone were determined in both directions by synthesizing a series of primers. The results show that the full-length cDNA contained in the 0660D02 clone is 1865bp (as shown in Seq IDN0: 1), and there is a 276p open reading frame (0RF) from 343bp to 618bp, which encodes a new protein (such as Seq ID NO: 2). We named this clone pBS-0660D02 and the encoded protein was named heparin-binding protein 10. Example 2 Domain analysis of cDNA clones
将本发明的肝素结合蛋白 10的序列及其编码的蛋白序列, 用 GCG中的 profile scan程序 (Basic local alignment search tool) [Altschul, SF et al. J.Mol. Biol.1990;215:403-10] , 在 pros i te等数据库进行结构域分析。 本发明的 肝素结合蛋白 10在 14-84与肝素结合蛋白特征性结构域有同源, 同源结果示于图 1, 同源率为 得分为 阈值为 7Z 。 实施例 3 用 RT-PCR方法克隆编码肝素结合蛋白 10的基因  The sequence of the heparin-binding protein 10 of the present invention and the protein sequence encoded by the heparin-binding protein 10 were analyzed using a profile scan program (Basic local alignment search tool) in GCG [Altschul, SF et al. J. Mol. Biol. 1990; 215: 403- 10], performing domain analysis in a database such as prosit. The heparin-binding protein 10 of the present invention is homologous with a characteristic domain of a heparin-binding protein at 14-84. The results of the homology are shown in FIG. 1, and the homology rate is a threshold of 7Z. Example 3 Cloning of a gene encoding heparin-binding protein 10 by RT-PCR
用胎脑细胞总 RNA为模板,以 oligo- dT为引物进行逆转录反应合成 cDNA,用 Qiagene的试剂盒纯化后,用下列引物进行 PCR扩增: Primer 1: 5'- AAATGTAAGAAAATATCAGGCACC -3' (SEQ ID NO: 3) Primer2: 5'- TTCTTTATGTGGCTTGCTGTTTGC -3' (SEQ ID NO: 4) CDNA was synthesized using fetal brain total RNA as a template and oligo-dT as a primer for reverse transcription reaction. After purification with Qiagene's kit, the following primers were used for PCR amplification: Primer 1: 5'- AAATGTAAGAAAATATCAGGCACC -3 '(SEQ ID NO: 3) Primer2: 5'- TTCTTTATGTGGCTTGCTGTTTGC -3' (SEQ ID NO: 4)
Primerl为位于 SEQ ID NO: 1的 5,端的第 lbp开始的正向序列;  Primerl is a forward sequence starting at lbp of the 5th end of SEQ ID NO: 1;
Primer2为 SEQ ID NO: 1的中的 3,端反向序列。  Primer2 is the 3, terminal reverse sequence of SEQ ID NO: 1.
扩增反应的条件: 在 50μΙ的反应体积中含有 50mmol/L KCI,10mmol/L Tris-HCl, pH8.5, 1.5mmol/L MgCl2, 200μιηο1/1 dNTP, lOpmol引物, 1U的 Taq DM聚 合酶(Clontech公司产品)。 在 PE9600型 DM热循环仪(Perkin-Elmer公司)上按下列 条件反应 25个周期: 94。C 30sec; 55°C 30sec; 72°C 2min0 在 RT-PCR时同时设 β - actin为阳性对照和模板空白为阴性对照。 扩增产物用 QIAGEN公司的试剂盒纯化, 用 TA克隆试剂盒连接到 pCR载体上 ( Invitrogen公司产品) 。 DNA序列分析结果表 明 PCR产物的 DNA序列与 SEQ ID NO: 1所示的 1- 1865bp完全相同。 实施例 4 Northern 印迹法分析肝素结合蛋白 10基因的表达 Conditions for the amplification reaction: 50 mmol / L KCI, 10 mmol / L Tris-HCl, pH 8.5, 1.5 mmol / L MgCl 2 , 200 μιηο 1/1 dNTP, lOpmol primer, 1U Taq DM polymerase (Clontech). The reaction was performed on a PE9600 DM thermal cycler (Perkin-Elmer) for 25 cycles under the following conditions: 94. C 30sec; 55 ° C 30sec; 72 ° C 2min 0 At the same time, set β-actin as a positive control and template blank as a negative control during RT-PCR. The amplified product was purified using a QIAGEN kit, and ligated to a pCR vector (Invitrogen product) using a TA cloning kit. The DNA sequence analysis results showed that the DNA sequence of the PCR product was exactly the same as that of 1 to 1865 bp shown in SEQ ID NO: 1. Example 4 Analysis of Heparin Binding Protein 10 Gene Expression by Northern Blotting
用一步法提取总 RNA[Anal. Biochem 1987, 162, 156-159]。 该法包括酸性硫 氰酸胍苯酚-氯仿抽提。 即用 4M异硫氰酸胍- 25mM柠檬酸钠, 0.2M乙酸钠 ( pH4.0 ) 对组织进行匀桨, 加入 1倍体积的苯酚和 1/5体积的氯仿-异戊醇 (49: 1 ) , 混合 后离心。 吸出水相层, 加入异丙醇 (0.8体积) 并将混合物离心得到 RNA沉淀。 将 得到的 RNA沉淀用 70%乙醇洗涤, 干燥并溶于水中。 用 20μ§ RNA, 在含 20mM 3- ( N- 吗啉代) 丙磺酸 (PH7.0) - 5mM乙酸钠 - ImM EDTA-2.2M甲醛的 1.2%琼脂糖凝胶上进 行电泳。 然后转移至硝酸纤维素膜上。 用 a-32P dATP通过随机引物法制备 32Ρ-标记 的 DM探针。 所用的 DM探针为图 1所示的 PCR扩增的肝素结合蛋白 10编码区序列 (343bp至 618bp)。 将 32P-标记的探针 (约 2 χ 106cpm/ml ) 与转移了 RNA的硝酸纤维 素膜在一溶液中于 42°C杂交过夜, 该溶液包含 50%甲酰胺 -25mM KH2P04 ( PH7.4 ) -5 χ SSC- 5 χ Denhardt's溶液和 20(^g/ml鲑精 DNA。 杂交之后, 将滤膜在 l x SSC- 0.1%SDS中于 55°C洗 30min。 然后, 用 Phosphor Imager进行分析和定量。 实施例 5 重组肝素结合蛋白 10的体外表达、 分离和纯化 Total RNA was extracted in one step [Anal. Biochem 1987, 162, 156-159]. This method involves acid guanidinium thiocyanate phenol-chloroform extraction. That is, 4M guanidine isothiocyanate-25mM sodium citrate, 0.2M sodium acetate (pH4.0) were used to uniformly paddle the tissue, and 1 volume of phenol and 1/5 volume of chloroform-isoamyl alcohol (49: 1) were added. ), Mix and centrifuge. Aspirate the aqueous layer, add isopropanol (0.8 vol) and centrifuge the mixture to obtain RNA precipitate. The resulting RNA pellet was washed with 70% ethanol, dried and dissolved in water. Using 20 μ § RNA, electrophoresis was performed on a 1.2% agarose gel containing 20 mM 3- (N-morpholino) propanesulfonic acid (PH7.0)-5 mM sodium acetate-1 mM EDTA-2.2M formaldehyde. It was then transferred to a nitrocellulose membrane. Preparation 32 Ρ- DM probe labeled with a- 32 P dATP by random priming method. The DM probe used was the PCR amplified heparin binding protein 10 coding region sequence (343bp to 618bp) shown in FIG. 1. A 32P-labeled probe (approximately 2 x 10 6 cpm / ml) was hybridized with a nitrocellulose membrane to which RNA was transferred at 42 ° C overnight in a solution containing 50% formamide-25mM KH 2 P0 4 ( P H7.4) -5 χ SSC-5 χ Denhardt's solution and 20 ^ g / ml salmon sperm DNA. After hybridization, the filter was washed in lx SSC-0.1% SDS at 55 ° C for 30 minutes. Then, use Analysis and quantification using Phosphor Imager. Example 5 In vitro expression, isolation and purification of recombinant heparin-binding protein 10
根据 SEQ ID NO: 1和图 1所示的编码区序列, 设计出一对特异性扩增引物, 序 列如下:  Based on SEQ ID NO: 1 and the coding region sequence shown in Figure 1, a pair of specific amplification primers were designed, the sequence is as follows:
Primer3: 5'- CCCCATATGATGTCCCTCCAGTTCAAAATCAAC -3' ( Seq ID No: 5 )  Primer3: 5'- CCCCATATGATGTCCCTCCAGTTCAAAATCAAC -3 '(Seq ID No: 5)
Primer 4: 5'- CCCGAGCTCTTACCATCTTCTGCAATCAAGTGA -3' (Seq ID No: 6 ) 此两段引物的 5'端分别含有 Ndel和 Sacl酶切位点, 其后分别为目的基因 5'端和 3,端的编码序列, Ndel和 Sacl酶切位点相应于表达载体质粒 pET- 28b (+) (Novagen公 司产品, Cat. No. 69865. 3)上的选择性内切酶位点。 以含有全长目的基因的 pBS- 0660D02质粒为模板, 进行 PCR反应。 PCR反应条件为: 总体积 50μ1中含 pBS- 0660D02 质粒 10pg、 引物 Primer-3和 Pr imer-4分另1 J为 l Opmol、 Advantage polymerase Mi xPrimer 4: 5'- CCCGAGCTCTTACCATCTTCTGCAATCAAGTGA -3 '(Seq ID No: 6) The 5' ends of these two primers contain Ndel and Sacl digestion sites, respectively, followed by the 5 'end and 3. The coding sequence at the end, the Ndel and Sacl restriction sites correspond to the selective endonuclease sites on the expression vector plasmid pET-28b (+) (Novagen, Cat. No. 69865. 3). The pBS-0660D02 plasmid containing the full-length target gene was used as a template for the PCR reaction. The PCR reaction conditions were as follows: 10 pg of plasmid pBS-0660D02, primers Primer-3 and Primer-4 in 50 μ1 total volume, 1 J Opmol, Advantage polymerase Mi x
( Clontech公司产品) 1μ1。 循环参数: 94°C 20s, 60°C 30s, 68°C 2 min,共 25个 循环。 用 Ndel和 Sacl分别对扩增产物和质粒 pET-28 (+)进行双酶切,分别回收大片 段,并用 T4连接酶连接。 连接产物转化用氯化钙法大肠杆细菌 DH5 o,在含卡那霉素(Clontech) 1μ1. Cycle parameters: 94 ° C 20s, 60 ° C 30s, 68 ° C 2 min, a total of 25 cycles. Ndel and Sacl were used to double digest the amplified product and plasmid pET-28 (+), respectively, and large fragments were recovered and ligated with T4 ligase. The ligation product was transformed into Ca. bacillus DH5o by the calcium chloride method.
(终浓度 3(^g/ml ) 的1^平板培养过夜后, 用菌落 PCR方法筛选阳性克隆, 并进行 测序。 挑选序列正确的阳性克隆(PET-0660D02 )用氯化钙法将重组质粒转化大肠 杆菌 BL21 (DE3) plySs (Novagen公司产品)。 在含卡那霉素 (终浓度 30μ8/ηι1 ) 的 LB 液体培养基中, 宿主菌 BL21 ( pET-0660D02 ) 在 37°C培养至对数生长期, 加入 IPTG 至终浓度 1謡 ol /L, 继续培养 5小时。 离心收集菌体, 经超声波破菌,离心收集上清 液, 用能与 6个组氨酸 Hi s-Tag ) 结合的亲和层析柱 Hi s. Bind Qui ck Car tr idge(The final concentration of 3 (^ g / ml)) was cultured overnight in a 1 ^ plate. The positive clones were screened by colony PCR and sequenced. The positive clones (PET-0660D02) with the correct sequence were selected and the recombinant plasmid was transformed by the calcium chloride method. E. coli BL21 (DE3) plySs (product of Novagen). In a LB liquid medium containing kanamycin (final concentration 30 μ 8 / ηι1), the host strain BL21 (pET-0660D02) was cultured at 37 ° C to logarithm. During the growth period, add IPTG to a final concentration of 1 謡 ol / L, and continue to culture for 5 hours. Centrifuge the bacteria to collect the bacteria, sonicate the bacteria, and centrifuge to collect the supernatant. Affinity chromatography column His s. Bind Qui ck Car tr idge
( Novagen公司产品) 进行层析, 得到了纯化的目的蛋白肝素结合蛋白 10。 经 SDS - PAGE电泳, 在 10kDa处得到一单一的条带(图 2 )。 将该条带转移至 PVDF膜上用 Edams 水解法进行 N-端氨基酸序列分析, 结果 N-端 15个氨基酸与 SEQ ID NO: 2所示的 N -端 15个氨基酸残基完全相同。 实施例 6 抗肝素结合蛋白 10抗体的产生 (Product of Novagen). Chromatography was performed to obtain purified heparin-binding protein 10 of interest. After SDS-PAGE electrophoresis, a single band was obtained at 10 kDa (Figure 2). This band was transferred to a PVDF membrane and the N-terminal amino acid sequence was analyzed by Edams hydrolysis method. As a result, the 15 amino acids at the N-terminus were identical to the 15 amino acid residues at the N-terminus shown in SEQ ID NO: 2. Example 6 Production of anti-heparin-binding protein 10 antibodies
用多肽合成仪 (PE公司产品)合成下述肝素结合蛋白 10特异性的多肽: NH2-Met-Ser-Leu-Gln-Phe-Lys-Ile-Asn-Leu-Ser-Lys-Thr-Lys-Gln-Glu-C00H (SEQ ID NO: 7)。 将该多肽分别与血蓝蛋白和牛血清白蛋白耦合形成复合物, 方法 参见: Avrameas, et a l. Imnumochemi s try, 1969; 6: 43。 用 4mg上述血蓝蛋白多狀 复合物加上完全弗氏佐剂免疫家兔, 15天后再用血蓝蛋白多肽复合物加不完全弗 氏佐剂加强免疫一次。 采用经 15 g/ml牛血清白蛋白多肽复合物包被的滴定板做 ELISA测定兔血清中抗体的滴度。 用蛋白 A-Sepharose从抗体阳性的家兔血清中分 离总 IgG。 将多肽结合于溴化氰活化的 Sepharose4B柱上, 用亲和层析法从总 IgG中 分离抗多肽抗体。 免疫沉淀法证明纯化的抗体可特异性地与肝素结合蛋白 10结合。 实施例 7 本发明的多核苷酸片段用作杂交探针的应用  Polypeptide synthesizer (product of PE company) was used to synthesize the following specific peptides of heparin-binding protein 10: -Glu-C00H (SEQ ID NO: 7). The polypeptide is coupled to hemocyanin and bovine serum albumin to form a complex. For methods, see: Avrameas, et al. Imnumochemi s try, 1969; 6:43. Rabbits were immunized with 4 mg of the hemocyanin polymorphic complex plus complete Freund's adjuvant, and 15 days later, the hemocyanin polypeptide complex plus incomplete Freund's adjuvant was used to boost immunity once. A titer plate coated with a 15 g / ml bovine serum albumin peptide complex was used as an ELISA to determine antibody titers in rabbit serum. Total IgG was isolated from antibody-positive rabbit sera using protein A-Sepharose. The peptide was bound to a cyanogen bromide-activated Sepharose4B column, and anti-peptide antibodies were separated from the total IgG by affinity chromatography. The immunoprecipitation method demonstrated that the purified antibody specifically binds to heparin-binding protein 10. Example 7 Application of the polynucleotide fragment of the present invention as a hybridization probe
从本发明的多核苷酸中挑选出合适的寡核苷酸片段用作杂交探针有多方面的 用途, 如用该探针可与不同来源的正常组织或病理组织的基因组或 cDM文库杂交 以鉴定其是否含有本发明的多核苷酸序列和检出同源的多核苷酸序列,进一步还可 用该探针检测本发明的多核苻酸序列或其同源的多核苷酸序列在正常组织或病理 组织细胞中的表达是否异常。 Selecting suitable oligonucleotide fragments from the polynucleotides of the present invention has various uses as hybridization probes. For example, the probes can be used to hybridize to the genome or CDM library of normal tissue or pathological tissue from different sources. In order to identify whether it contains the polynucleotide sequence of the present invention and detect a homologous polynucleotide sequence, the probe can further be used to detect the polynucleotide sequence of the present invention or its homologous polynucleotide sequence in normal tissue or Whether the expression in pathological tissue cells is abnormal.
本实施例的目的是从本发明的多核苷酸 SEQ ID NO: 1 中挑选出合适的寡核苷 酸片段用作杂交探针, 并用滤膜杂交方法鉴定一些组织中是否含有本发明的多核 苷酸序列或其同源的多核苷酸序列。 滤膜杂交方法包括斑点印迹法、 Southern 印 迹法、 Nor thern 印迹法和复印方法等, 它们都是将待测的多核苷酸样品固定在滤 膜上后使用基本相同的步骤杂交。 这些相同的步骤是: 固定了样品的滤膜首先用 不含探针的杂交缓冲液进行预杂交, 以使滤膜上样品的非特异性的结合部位被载 体和合成的多聚物所饱和。 然后预杂交液被含有标记探针的杂交缓冲液替换, 并 保温使探针与靶核酸杂交。 杂交步骤之后, 未杂交上的探针被一系列洗膜步骤除 掉。 本实施例利用较高强度的洗膜条件 (如较低盐浓度和较高的温度), 以使杂交 背景降低且只保留特异性强的信号。 本实施例选用的探针包括两类: 第一类探针 是完全与本发明的多核苷酸 SEQ ID NO: 1相同或互补的寡核苷酸片段; 第二类探 针是部分与本发明的多核苷酸 SEQ ID NO: 1相同或互补的寡核苷酸片段。 本实施 例选用斑点印迹法将样品固定在滤膜上, 在较高强度的的洗膜条件下, 第一类探 针与样品的杂交特异性最强而得以保留。  The purpose of this embodiment is to select a suitable oligonucleotide fragment from the polynucleotide SEQ ID NO: 1 of the present invention as a hybridization probe, and to identify whether some tissues contain the polynucleoside of the present invention by a filter hybridization method. Acid sequence or a homologous polynucleotide sequence thereof. Filter hybridization methods include dot blotting, Southern imprinting, Nor thern blotting, and copying methods. They all use the same steps to fix the polynucleotide sample to be tested on the filter and then hybridize. These same steps are as follows: The sample-immobilized filter is first pre-hybridized with a probe-free hybridization buffer to saturate the non-specific binding site of the sample on the filter with the carrier and the synthesized polymer. The pre-hybridization solution is then replaced with a hybridization buffer containing labeled probes and incubated to hybridize the probes to the target nucleic acid. After the hybridization step, the unhybridized probes are removed by a series of membrane washing steps. This embodiment uses higher-intensity washing conditions (such as lower salt concentration and higher temperature) to reduce the hybridization background and retain only strong specific signals. The probes used in this embodiment include two types: the first type of probes are oligonucleotide fragments that are completely the same as or complementary to the polynucleotide SEQ ID NO: 1 of the present invention; the second type of probes are partially related to the present invention The polynucleotide SEQ ID NO: 1 is the same or complementary oligonucleotide fragment. In this example, the dot blot method is used to fix the sample on the filter membrane. Under the high-intensity washing conditions, the first type of probe and the sample have the strongest hybridization specificity and are retained.
一、 探针的选用  First, the selection of the probe
从本发明的多核苷酸 SEQ ID NO: 1 中选择寡核苷酸片段用作杂交探针, 应遵 循以下原则和需要考虑的几个方面:  The selection of oligonucleotide fragments for use as hybridization probes from the polynucleotide SEQ ID NO: 1 of the present invention should follow the following principles and several aspects to be considered:
1 , 探针大小优选范围为 18-50个核苷酸;  1. The preferred range of probe size is 18-50 nucleotides;
2 , GC含量为 30%-70%, 超过则非特异性杂交增加;  2.GC content is 30% -70%, non-specific hybridization increases when it exceeds;
3, 探针内部应无互补区域;  3. There should be no complementary regions inside the probe;
4, 符合以上条件的可作为初选探针, 然后进一步作计算机序列分析, 包 括将该初选探针分别与其来源序列区域 (即 SEQ ID NO: 1 ) 和其它已知的基因组 序列及其互补区进行同源性比较, 若与非靶分子区域的同源性大于 85%或者有超过 15个连续碱基完全相同, 则该初选探针一般就不应该使用;  4. Those that meet the above conditions can be used as primary selection probes, and then further computer sequence analysis, including the primary selection probe and its source sequence region (ie, SEQ ID NO: 1) and other known genomic sequences and their complements The regions are compared for homology. If the homology with the non-target molecular region is greater than 85% or there are more than 15 consecutive bases, the primary probe should not be used;
5 , 初选探针是否最终选定为有实际应用价值的探针还应进一步由实验确 定。  5. Whether the preliminary selection probe is finally selected as a probe with practical application value should be further determined by experiments.
完成以上各方面的分析后挑选并合成以下二个探针:  After completing the above analysis, select and synthesize the following two probes:
探针 1 ( probel ), 属于第一类探针, 与 SEQ ID NO: 1 的基因片段完全同源 或互补(41Nt ) 5'- TGTCCCTCCAGTTCAAAATCAACCTHCGAAAACAAAACAA -3' ( SEQ ID NO: 8 ) 探针 2 ( probe2 ), 属于第二类探针, 相当于 SEQ ID NO: 1 的基因片段或其 互补片段的替换突变序列 (41Nt ): Probe 1 (probel), which belongs to the first type of probe, is completely homologous or complementary to the gene fragment of SEQ ID NO: 1 (41Nt) 5'- TGTCCCTCCAGTTCAAAATCAACCTHCGAAAACAAAACAA -3 '(SEQ ID NO: 8) Probe 2 (probe2), which belongs to the second type of probe, is equivalent to the replacement mutant sequence of the gene fragment of SEQ ID NO: 1 or its complementary fragment (41Nt):
5'- TGTCCCTCCAGTTCAAAGTCAACCTTTCGAAAACAAAACAA -3' ( SEQ ID NO: 9 ) 与以下具体实验步骤有关的其它未列出的常用试剂及其配制方法请参考文 献: DNA PROBES G. H. Kel ler; M. M, Manak; Stockton Press, 1989 (USA)以及更常 用的分子克隆实验手册书籍如 《分子克隆实验指南》 U998年第二版) [美]萨姆布 鲁克等著, 科学出版社。  5'- TGTCCCTCCAGTTCAAAGTCAACCTTTCGAAAACAAAACAA -3 '(SEQ ID NO: 9) For other commonly used reagents and their preparation methods not related to the following specific experimental procedures, please refer to the literature: DNA PROBES GH Kel ler; M. M, Manak; Stockton Press , 1989 (USA) and more commonly used molecular cloning experiment manuals such as "Molecular Cloning Experiment Guide" U998 2nd Edition. [US] Sambrook et al., Science Press.
样品制备:  Sample Preparation:
1 , 从新鲜或冰冻组织中提取 DNA  1.Extract DNA from fresh or frozen tissue
步骤: 1 )将新鲜或新鲜解冻的正常肝组织放入浸在冰上并盛有磷酸盐缓冲液 (PBS) 的平 中。 用剪刀或手术刀将组织切成小块。 操作中应保持组织湿润。 2 ) 以 lOOOg离心切碎组织 10分钟。 3)用冷匀浆缓冲液 ( 0.25mol/L蔗糖; 25麵 ol/L Tris-HCl, pH7.5; 25mmol/L NaCl; 25讓 ol/L MgCl2 ) 悬浮沉淀 (大约 lOml/g )。 4 ) 在 4°C 用电动匀浆器以全速匀浆组织悬液, 直至组织被完全破碎。 5 ) lOOOg 离心 10分钟。 6 )用重悬细胞沉淀(每 0. lg最初组织样品加 l-5ml ), 再以 lOOOg离心 10分钟。 7 )用裂解缓冲液重悬沉淀 (每 0. lg最初组织样品加 lml ), 然后接以下 的苯酚抽提法。 Steps: 1) Place fresh or freshly thawed normal liver tissue in a flat immersed in ice and filled with phosphate buffered saline (PBS). Cut the tissue into small pieces with scissors or a scalpel. Keep tissue moist during operation. 2) Centrifuge the tissue at 1,000 g for 10 minutes. 3) Suspend the precipitate (about 10 ml / g) with cold homogenization buffer (0.25 mol / L sucrose; 25 sides ol / L Tris-HCl, pH 7.5; 25 mmol / L NaCl; 25 let ol / L MgCl 2 ). 4) Homogenize the tissue suspension at 4 ° C at full speed with an electric homogenizer until the tissue is completely broken. 5) Centrifuge at 1000g for 10 minutes. 6) Resuspend the cell pellet (l-5ml per 0.1 g of the initial tissue sample), and centrifuge at 1,000 g for 10 minutes. 7) Resuspend the pellet with lysis buffer (add 1 ml per 0.1 g of the initial tissue sample), and then follow the following phenol extraction method.
2, DNA的苯酚抽提法  2, DNA phenol extraction method
步骤: 1 )用 1- 10ml 冷 PBS洗细胞, 1000g离心 10分钟。 2 )用冷细胞裂解 液重悬浮沉淀的细胞 (Ι χ ΙΟ8细胞 /ml ) 最少应用 lOOul 裂解缓冲液。 3) 加 SDS 至终浓度为 1%, 如果在重悬细胞之前将 SDS 直接加入到细胞沉淀中, 细胞可能会 形成大的团块而难以破碎, 并降低总产率。 这一点在抽提 >107细胞时特别严重。 4 ) 加蛋白酶 K至终浓度 200ug/ml。 5 ) 50°C保温反应 1小时或在 37°C轻轻振摇过夜。 6 )用等体积苯酚: 氯仿: 异戊醇 ( 25: 24: 1 ) 抽提, 在小离心机管中离心 10分 钟。 两相应清楚分离, 否则重新进行离心。 7 ) 将水相转移至新管。 8 ) 用等体积 氯仿: 异戊醇 (24: 1 )抽提, 离心 10分钟。 9 )将含 DNA的水相转移至新管。 然 后进行 DM的纯化和乙醇沉淀。 Steps: 1) Wash cells with 1-10 ml of cold PBS and centrifuge at 1000 g for 10 minutes. 2) Resuspend the pelleted cells with cold cell lysate (1 x 10 8 cells / ml) and apply a minimum of 100 ul of lysis buffer. 3) Add SDS to a final concentration of 1%. If SDS is added directly to the cell pellet before resuspending the cells, the cells may form large clumps that are difficult to break, and reduce the overall yield. This is particularly serious when extracting> 10 7 cells. 4) Add proteinase K to a final concentration of 200ug / ml. 5) Incubate at 50 ° C for 1 hour or shake gently at 37 ° C overnight. 6) Extract with an equal volume of phenol: chloroform: isoamyl alcohol (25: 24: 1) and centrifuge in a small centrifuge tube for 10 minutes. The two should be clearly separated, otherwise centrifuge again. 7) Transfer the water phase to a new tube. 8) Extract with an equal volume of chloroform: isoamyl alcohol (24: 1) and centrifuge for 10 minutes. 9) Transfer the DNA-containing aqueous phase to a new tube. Purification of DM and ethanol precipitation were then performed.
3, DM的纯化和乙醇沉淀  3. Purification and ethanol precipitation of DM
步骤: 1 )将 1 0体积 2mol/L醋酸纳和 2倍体积冷 100%乙醇加到 DNA溶液 中, 混匀。 在 -20°C放置 1 小时或过夜。 2 ) 离心 10分钟。 3)小心吸出或倒出乙 醇。 4 )用 70%冷乙醇 500ul洗涤沉淀, 离心 5分钟。 5)小心吸出或倒出乙醇。 用 500ul 冷乙醇洗涤沉淀, 离心 5 分钟。 6)小心吸出或倒出乙醇, 然后在吸水纸上 倒置使残余乙醇流尽。 空气干燥 10-15 分钟, 以使表面乙醇挥发。 注意不要使沉 淀完全干燥, 否则较难重新溶解。 7) 以小体积 TE或水重悬 DNA 沉淀。 低速涡旋 振荡或用滴管吹吸, 同时逐渐增加 TE, 混合至 DM充分溶解, 每 1- 5 χ 106细胞所 提取的大约加 lul。 Steps: 1) Add 10 volumes of 2mol / L sodium acetate and 2 volumes of cold 100% ethanol to the DNA solution and mix. Leave at -20 ° C for 1 hour or overnight. 2) Centrifuge for 10 minutes. 3) Carefully aspirate or pour out the ethanol. 4) Wash the pellet with 500ul of 70% cold ethanol and centrifuge for 5 minutes. 5) Carefully aspirate or pour out the ethanol. use Wash the pellet with 500ul of cold ethanol and centrifuge for 5 minutes. 6) Carefully aspirate or pour out the ethanol, then invert on the absorbent paper to drain off the residual ethanol. Air dry for 10-15 minutes to allow the surface ethanol to evaporate. Be careful not to allow the pellet to dry completely, otherwise it will be more difficult to re-dissolve. 7) Resuspend the DNA pellet in a small volume of TE or water. Low-speed vortexing or pipetting, with a dropper, while gradually increasing the TE, mixed until fully dissolved DM, 106 cells per 1- 5 χ extracted plus about lul.
以下第 8-13步骤仅用于必须除去污染时, 否则可直接进行第 14步骤。  The following steps 8-13 are only used when contamination must be removed, otherwise step 14 can be performed directly.
8 ) 将 RNA酶 A加到 DNA溶液中, 终浓度为 100ug/ml, 37°C保温 30分钟。 9) 加入 SDS和蛋白酶 K, 终浓度分别为 0.5%和 100ug/ml。 37°C保温 30分钟。 10) 用等体积的苯酚: 氯仿: 异戊醇 ( 25: 24: 1 )抽提反应液, 离心 10 分钟。 11 ) 小心移出水相, 用等体积的氯仿: 异戊醇 (24: 1 ) 重新抽提, 离心 10分钟。 12) 小心移出水相, 加 1/10体积 2mol/L醋酸钠和 2.5体积冷乙醇, 混匀置 - 20°C 1小 时。 13) 用 70%乙醇及 100%乙醇洗涤沉淀, 空气干燥, 重悬核酸, 过程同第 3 - 6 步骤。 )测定 A26。和 A28。以检测 DNA的纯度及产率。 15)分装后存放于 -20° (:。 8) Add RNase A to the DNA solution to a final concentration of 100ug / ml, and incubate at 37 ° C for 30 minutes. 9) Add SDS and proteinase K to the final concentration of 0.5% and 100ug / ml. Incubate at 37 ° C for 30 minutes. 10) Extract the reaction solution with an equal volume of phenol: chloroform: isoamyl alcohol (25: 24: 1) and centrifuge for 10 minutes. 11) Carefully remove the aqueous phase, re-extract with an equal volume of chloroform: isoamyl alcohol (24: 1), and centrifuge for 10 minutes. 12) Carefully remove the aqueous phase, add 1/10 volume of 2mol / L sodium acetate and 2.5 volumes of cold ethanol, and mix well--20 ° C for 1 hour. 13) Wash the pellet with 70% ethanol and 100% ethanol, air dry, and resuspend the nucleic acid. The process is the same as steps 3-6. ) Determine A 26 . And A 28 . To detect the purity and yield of DNA. 15) Store at -20 ° (:) after packing.
样膜的制备:  Preparation of sample film:
1)取 4 x 2 张适当大小的硝酸纤维素膜 (NC膜), 用铅笔在其上轻轻标出 点样位置及样号, 每一探针需两张 NC膜, 以便在后面的实验步骤中分别用高强度 条件和强度条件洗膜 。  1) Take 4 x 2 pieces of nitrocellulose membrane (NC membrane) of appropriate size, and mark the spotting position and sample number on it with a pencil. Two NC membranes are needed for each probe for later experiments. In the step, the film is washed with high-strength conditions and strength conditions, respectively.
2) 吸取及对照各 15微升, 点于样膜上, 在室温中晾干。  2) Pipette and control 15 microliters each, spot on the sample film, and dry at room temperature.
3 ) 置于浸润有 0. lmol/L NaOH, 1.5mol/L NaCl的滤纸上 5分钟 (两次), 晾干置于浸润有 0.5raol/L Tris-HCl ( pH7.0 ), 3mol/L NaCl 的滤纸上 5分钟 (两 次), 晾干。  3) Place on filter paper infiltrated with 0.1 mol / L NaOH, 1.5 mol / L NaCl for 5 minutes (twice), and dry in 0.5raol / L Tris-HCl (pH 7.0), 3 mol / L NaCl filter paper for 5 minutes (twice) and allowed to dry.
4) 夹于干净滤纸中, 以铝箔包好, 60-80°C真空干燥 2小时。  4) Clamped in clean filter paper, wrapped in aluminum foil, and dried under vacuum at 60-80 ° C for 2 hours.
探针的标记  Labeling of probes
1 ) 3μ1 Probe ( 0. IOD/Ιθμΐ ), 加入 2μ1 Kinase缓冲液, 8-10 uCi γ- 32P- dATP+2U Kinase, 以补加至终体积 20μ1。 1) 3μ1 Probe (0.1OD / Ιθμΐ), add 2μ1 Kinase buffer, 8-10 uCi γ- 32 P-dATP + 2U Kinase, to make up to a final volume of 20μ1.
2 ) 37 °C 保温 2小时。  2) Incubate at 37 ° C for 2 hours.
3)加 1/5体积的溴酚蓝指示剂 (BPB)。  3) Add 1/5 volume of Bromophenol Blue Indicator (BPB).
4)过 Sephadex G- 50柱。  4) Pass Sephadex G-50 column.
5 ) 至有 32P-Probe洗出前开始收集第一峰(可用 Monitor监测;)。 5) Start collecting the first peak before 32 P-Probe washes out (can be monitored by Monitor;).
6) 5滴 /管, 收集 10- 15管。  6) 5 drops / tube, collect 10-15 tubes.
7)用液体闪烁仪监测同位素量。  7) Monitor the amount of isotope with a liquid scintillator.
8)合并第一峰的收集液后即为所需制备的 32P- Probe (第二峰为游离 γ- 32P - dATP )。 8) The 32 P-Probe (the second peak is free γ- 32 P- dATP).
预杂交  Pre-hybridization
将样膜置于塑料袋中,加入 3-1 Omg预杂交液( l OxDenhardf s ; 6xSSC, 0. lmg/ml CT DM (小牛胸腺 DNA ) )。 封好袋口后, 68°C水洛摇 2小时。  The sample membrane was placed in a plastic bag, and 3-1 Omg pre-hybridization solution (OxDenhardf s; 6xSSC, 0.1 mg / ml CT DM (calf thymus DNA)) was added. After sealing the bag, shake at 68 ° C for 2 hours.
杂交  Cross
将塑料袋剪去一角, 加入制备好的探针, 封好袋口后, 42°C水浴摇过夜。 洗膜:  Cut a corner of the plastic bag, add the prepared probe, seal the bag, and shake it at 42 ° C in a water bath overnight. Wash film:
高强度洗膜:  High-intensity washing film:
1 )取出已杂交好的样膜。  1) Take out the hybridized sample membrane.
2 ) 2xSSC, 0. 1%SDS中, 40°C洗 15分钟 ( 2次)。  2) 2xSSC, 0.1% SDS, wash at 40 ° C for 15 minutes (twice).
3 ) 0. lxSSC, 0. 1%SDS中, 40。C洗 15分钟 ( 2次)。  3) 0.1xSSC, 0.1% SDS, 40. C Wash for 15 minutes (twice).
4 ) 0. l xSSC, 0. 1%SDS中, 55。C洗 30分钟 ( 2次), 室温晾干。 低强度洗膜:  4) 0.1 xSSC, 0.1% SDS, 55. Wash for 30 minutes (twice) and dry at room temperature. Low-intensity washing film:
1 )取出已杂交好的样膜。  1) Take out the hybridized sample membrane.
2 ) 2xSSC, 0. 1%SDS中, 37°C洗 15分钟 ( 2次)。  2) 2xSSC, 0.1% SDS, wash at 37 ° C for 15 minutes (twice).
3 ) 0. l xSSC, 0. 1%SDS中, 37。C洗 15分钟 ( 2次)。  3) 0.1 xSSC, 0.1% SDS, 37. C Wash for 15 minutes (twice).
4 ) 0. l xSSC, 0. 1%SDS中, 40。C洗 15分钟 ( 2次), 室温晾干。  4) 0.1 xSSC, 0.1% SDS, 40. Wash for 15 minutes (twice) and dry at room temperature.
X -光自显影: X-ray autoradiography:
-70°C, X-光自显影 (压片时间根据杂交斑放射性强弱而定)。  -70 ° C, X-ray autoradiography (compression time depends on the radioactivity of the hybrid spot).
实验结果:  Experimental results:
采用低强度洗膜条件所进行的杂交实验, 以上两个探针杂交斑放射性强弱没 有明显区别; 而釆用高强度洗膜条件所进行的杂交实验, 探针 1 的杂交斑放射性 强度明显强于另一个探针杂交斑的放射性强度。 因而可用探针 1 定性和定量地分 析本发明的多核苷酸在不同组织中的存在和差异表达。 实施例 8 DNA Microarray  The hybridization experiments performed under low-intensity membrane washing conditions showed no significant difference in the radioactive intensity of the above two probes. However, in the hybridization experiments performed under high-intensity membrane washing conditions, the radioactive intensity of probe 1 was significantly stronger. To the radioactive intensity of the hybridization spot of another probe. Therefore, the presence and differential expression of the polynucleotide of the present invention in different tissues can be analyzed qualitatively and quantitatively with the probe 1. Example 8 DNA Microarray
基因芯片或基因微矩阵 (DNA Mi croarray )是目前许多国家实验室和大制药 公司都在着手研制和开发的新技术, 它是指将大量的靶基因片段有序地、 高密度 地排列在玻璃、 硅等载体上, 然后用荧光检测和计算机软件进行数据的比较和分 析, 以达到快速、 高效、 高通量地分析生物信息的目的。 本发明的多核苷酸可作 为靶 D 用于基因芯片技术用于高通量研究新基因功能; 寻找和筛选组织特异性 新基因特别是肿瘤等疾病相关新基因; 疾病的诊断, 如遗传性疾病。 其具体方法 步骤在文献中已有多种报道, 如可参阅文献 DeRi s i, J. L. , Lyer, V. &Brown, P. 0. (1997) Sc ience278, 680-686.及文献 Hel le,R. A. , Schema, M. , Cha i, A. , Shalom, D. , (1997) PNAS 94: 2150-2155. Gene chip or gene micro matrix (DNA Mi croarray) is a new technology that many national laboratories and large pharmaceutical companies are currently developing and developing. It refers to the orderly and high density arrangement of a large number of target gene fragments on glass. , Silicon and other carriers, and then use fluorescence detection and computer software to compare and analyze the data, in order to achieve the purpose of rapid, efficient, high-throughput analysis of biological information. The polynucleotide of the present invention can be used as Targeting D for gene chip technology for high-throughput research on new gene functions; finding and screening new tissue-specific genes, especially new genes related to diseases such as tumors; diagnosis of diseases such as hereditary diseases. The specific method steps have been reported in the literature. For example, refer to the literature DeRi si, JL, Lyer, V. & Brown, P. 0. (1997) Sc ience 278, 680-686. And the literature Hel le, RA, Schema , M., Cha i, A., Shalom, D., (1997) PNAS 94: 2150-2155.
(一) 点样  (A) spotting
各种不同的全长 cDNA共计 4000条多核苷酸序列作为靶 DNA,其中包括本发明 的多核苷酸。 将它们分别通过 PCR 进行扩增, 纯化所得扩增产物后将其浓度调到 500ng/ul左右, 用 Cartes ian 7500点样仪(购自美国 Cartes ian公司)点于玻璃介 质上, 点与点之间的距离为 280μηι。 将点样后的玻片进行水合、 干燥, 置于紫外 交联仪中交联, 洗脱后干燥使 D 固定在玻璃片上制备成芯片。 其具体方法步骤 在文献中已有多种报道。 本实施例的点样后处理步骤是:  A total of 4,000 polynucleotide sequences of various full-length cDNAs are used as target DNA, including the polynucleotide of the present invention. They were respectively amplified by PCR. After purification, the concentration of the amplified product was adjusted to about 500 ng / ul, and spotted on a glass medium with a Cartesian 7500 spotter (purchased from Cartesian Company, USA). The distance between them is 280 μηι. The spotted slides were hydrated, dried, and cross-linked in a UV cross-linker. After elution, the slides were fixed to D to fix the slides to prepare chips. The specific method steps have been reported in the literature. The sample post-processing steps in this embodiment are:
1. 潮湿环境中水合 4小时;  1. Hydration in a humid environment for 4 hours;
2. G. 2%SDS洗涤 1分钟;  2. G. 2% SDS wash for 1 minute;
3. ddH20洗涤两次, 每次 1分钟; 3. Wash twice with ddH 2 0 for 1 minute each time;
4. NaBH4封闭 5分钟; 4. NaBH 4 is blocked for 5 minutes;
5. 95°C水中 2分钟;  5. 95 ° C water for 2 minutes;
6. G. 2%SDS洗涤 1分钟;  6. G. 2% SDS was washed for 1 minute;
7. ddH20冲洗两次; 7. Rinse twice with ddH 2 0;
8. 凉干, 25°C储存于暗处备用。  8. Dry and store at 25 ° C in the dark for future use.
(二)探针标记  (Two) probe marking
用一步法分别从正常 与 癌中抽提总 mRNA,并用 Ol igotex mRNA Midi Ki t (购 自 QiaGen 公司)纯化 mRNA,通过反转录分别将荧光试剂 Cy3dUTP (5- Amino- propargy 1-2' -deoxyuri dine 5'-tripha te coupled to C 3 f luorescent dye, 购 自 Amersham Phamacia Biotech 公司)标记正常 组织的 mRNA , 用荧光试剂 Cy5dUTP (5-Araino-propargy 1-2' -deoxyur i dine 5'-tr iphate coupled to Cy5 f luorescent dye, 购自 Amersham Phamac ia Biotech公司)标记^ ¾组织 mRNA, 经纯化后制备出探针。 具体步骤参照及方法见  Total mRNA was extracted from normal and cancer cells in one step, and mRNA was purified using Oligotex mRNA Midi Kit (purchased from QiaGen). The fluorescent reagent Cy3dUTP (5- Amino- propargy 1-2 '- deoxyuri dine 5'-tripha te coupled to C 3 f luorescent dye, purchased from Amersham Phamacia Biotech Company, labeled mRNA of normal tissues, using a fluorescent reagent Cy5dUTP (5-Araino-propargy 1-2 '-deoxyur i dine 5'-tr iphate coupled to Cy5 fluorescent dye (purchased from Amersham Phamac ia Biotech)) labeled ^ ¾ tissue mRNA, and the probe was prepared after purification. For specific steps and methods, see
Schena, M. , Shalon, D., Hel ler, R. (1996) Proc. Nat l. Acad. Sci. USA. Vol. 93: 10614-10619. Schena, M., Sha lon, Dar i., Davi s, R. W. (1995) Science. 270 (20): 467-480.  Schena, M., Shalon, D., Hel ler, R. (1996) Proc. Nat l. Acad. Sci. USA. Vol. 93: 10614-10619. Schena, M., Sha lon, Dar i., Davi s, RW (1995) Science. 270 (20): 467-480.
(三) 杂交  (Three) cross
分别将来自 以上两种组织的探针与芯片一起在 UniHyb™ Hybr idizat ion Solution (购自 TeleChem 公司)杂交液中进行杂交 16 小时, 室温用洗涤液 (1 χ SSC, 0.2%SDS ) 洗涤后用 ScanArray 3000扫描仪 (购自美国 General Scanning公 司)进行扫描, 扫描的图象用 Imagene软件 (美国 Biodiscovery公司)进行数据 分析处理, 算出每个点的 Cy3/Cy5 比值, 该比值小于 0.5大于 2 的点被认为是表 达有差异的基因。 Combine the probes from the two tissues with the chips at UniHyb ™ Hybr idizat ion Solution (purchased from TeleChem) was used for hybridization for 16 hours, and washed with a washing solution (1 x SSC, 0.2% SDS) at room temperature, and then scanned with a ScanArray 3000 scanner (purchased from General Scanning, USA). The scanned image Imagene software (Biodiscovery, USA) was used for data analysis and processing, and the Cy3 / Cy5 ratio of each point was calculated. The points with the ratio less than 0.5 and greater than 2 were considered to be genes with different expression.
实验结果表明, Cy3 sigml= 1399. ( 取四次实验的平均值 ) , Cy5 signal=5539.02 (取四次实验的平均值) , Cy3/Cy5=A \^77%,本发明的多核苷酸 在以上两种组织中的表达 ■明显差异, 表明本发明的多核苷酸与 相关。  The experimental results show that Cy3 sigml = 1399. (take the average of four experiments), Cy5 signal = 5539.02 (take the average of four experiments), Cy3 / Cy5 = A \ ^ 77%, the polynucleotide of the present invention Significant differences in expression in the above two tissues indicate that the polynucleotides of the present invention are related.

Claims

利要求 Profit requirements
1、 一种分离的多肽-肝素结合蛋白 10, 其特征在于它包含有: SEQ ID NO: 2 所示的氨基酸序列的多肽、 或其多肽的活性片段、 类似物或衍生物。 1. An isolated polypeptide-heparin-binding protein 10, characterized in that it comprises: a polypeptide having the amino acid sequence shown in SEQ ID NO: 2, or an active fragment, analog, or derivative thereof.
2、 如权利要求 1所述的多肽, 其特征在于所述多肽、 类似物或衍生物的氨基 酸序列具有与 SEQ ID NO: 2所示的氨基酸序列至少 95%的相同性。  2. The polypeptide according to claim 1, characterized in that the amino acid sequence of the polypeptide, analog or derivative has at least 95% identity with the amino acid sequence shown in SEQ ID NO: 2.
3、 如权利要求 2所述的多肽, 其特征在于它包含具有 SEQ ID NO: 2所示的氨 基酸序列的多肽。  3. The polypeptide according to claim 2, characterized in that it comprises a polypeptide having an amino acid sequence shown in SEQ ID NO: 2.
4、 一种分离的多核苷酸, 其特征在于所述多核苷酸包含选自下组中的一种: 4. An isolated polynucleotide, characterized in that said polynucleotide comprises one selected from the group consisting of:
(a) 编码具有 SEQ ID NO: 2 所示氨基酸序列的多肽或其片段、 类似物、 衍生 物的多核苷酸; (a) a polynucleotide encoding a polypeptide having an amino acid sequence shown in SEQ ID NO: 2 or a fragment, analog, or derivative thereof;
(b) 与多核苷酸 ) 互补的多核苷酸; 或  (b) a polynucleotide complementary to the polynucleotide; or
(c) 与 (a )或 (b ) 有至少 70%相同性的多核苷酸。  (c) A polynucleotide that is at least 70% identical to (a) or (b).
5、 如权利要求 4 所述的多核苷酸, 其特征在于所述多核苷酸包含编码具有 SEQ ID NO: 2所示氨基酸序列的多核苷酸。  5. The polynucleotide according to claim 4, wherein the polynucleotide comprises a polynucleotide encoding an amino acid sequence represented by SEQ ID NO: 2.
6、如权利要求 4所述的多核苷酸,其特征在于所述多核苷酸的序列包含有 SEQ ID NO: 1中 343-618位的序列或 SEQ ID NO: 1中 1-1865位的序列。  6. The polynucleotide according to claim 4, characterized in that the sequence of the polynucleotide comprises the sequence of positions 343-618 in SEQ ID NO: 1 or the sequence of positions 1-1865 in SEQ ID NO: 1. .
7、 一种含有外源多核苷酸的重组载体, 其特征在于它是由权利要求 4-6中的 任一权利要求所述多核苷酸与质粒、 病毒或运载体表达载体构建而成的重组载体。  7. A recombinant vector containing an exogenous polynucleotide, characterized in that it is a recombinant constructed from the polynucleotide according to any one of claims 4 to 6 with a plasmid, virus or a carrier expression vector Carrier.
8、 一种含有外源多核苷酸的遗传工程化宿主细胞, 其特征在于它是选自于下 列一种宿主细胞:  8. A genetically engineered host cell containing an exogenous polynucleotide, characterized in that it is selected from one of the following host cells:
(a) 用权利要求 7所述的重组载体转化或转导的宿主细胞; 或  (a) a host cell transformed or transduced with the recombinant vector of claim 7; or
(b) 用权利要求 4-6中的任一权利要求所述多核苷酸转化或转导的宿主细胞。 (b) a host cell transformed or transduced with a polynucleotide according to any one of claims 4-6.
9、 一种具有肝素结合蛋白 10 活性的多肽的制备方法, 其特征在于所述方法 包括: 9. A method for preparing a polypeptide having heparin-binding protein 10 activity, characterized in that the method includes:
(a)在表达肝素结合蛋白 10条件下, 培养权利要求 8所述的工程化宿主细胞; (a) culturing the engineered host cell according to claim 8 under the condition that heparin-binding protein 10 is expressed;
(b) 从培养物中分离出具有肝素结合蛋白 10活性的多肽。 (b) Isolating a polypeptide having heparin-binding protein 10 activity from the culture.
10、 一种能与多肽结合的抗体,其特征在于所述抗体是能与肝素结合蛋白 1 0 特异性结合的抗体。  10. An antibody capable of binding to a polypeptide, characterized in that said antibody is an antibody capable of specifically binding to heparin-binding protein 10.
11、 一类模拟或调节多肽活性或表达的化合物, 其特征在于它们是模拟、 促 进、 拮抗或抑制肝素结合蛋白 10的活性的化合物。  11. A class of compounds that mimic or regulate the activity or expression of a polypeptide, characterized in that they are compounds that mimic, promote, antagonize or inhibit the activity of heparin-binding protein 10.
12、 如权利要求 11所述的化合物, 其特征在于它是 SEQ ID NO: 1所示的多核 苷酸序列或其片段的反义序列。 12. The compound according to claim 11, characterized in that it is a multi-core as shown in SEQ ID NO: 1 Antisense sequence of a nucleotide sequence or a fragment thereof.
13、 一种权利要求 11所述化合物的应用, 其特征在于所述化合物用于调节肝 素结合蛋白 10在体内、 体外活性的方法。  13. Use of a compound according to claim 11, characterized in that the compound is used for a method for regulating the activity of heparin-binding protein 10 in vivo and in vitro.
14、 一种检测与权利要求 1-3 中的任一权利要求所述多肽相关的疾病或疾病 易感性的方法, 其特征在于其包括检测所述多肽的表达量, 或者检测所述多肽的 活性, 或者检测多核苷酸中引起所述多肽表达量或活性异常的核苷酸变异。  14. A method for detecting a disease or susceptibility to a disease associated with a polypeptide according to any one of claims 1-3, characterized in that it comprises detecting the expression level of the polypeptide, or detecting the activity of the polypeptide Or detecting a nucleotide variation in a polynucleotide that causes abnormal expression or activity of the polypeptide.
15、 如权利要求 1-3 中的任一权利要求所述多肽的应用, 其特征在于它应用 于筛选肝素结合蛋白 10的模拟物、 激动剂, 拮抗剂或抑制剂; 或者用于肽指紋图 谱鉴定。  15. Use of a polypeptide according to any one of claims 1-3, characterized in that it is used for screening mimetics, agonists, antagonists or inhibitors of heparin binding protein 10; or for peptide fingerprinting Identification.
16、 如权利要求 4-6 中的任一权利要求所述的核酸分子的应用, 其特征在于 它作为引物用于核酸扩增反应, 或者作为探针用于杂交反应, 或者用于制造基因 芯片或微阵列。  16. The use of a nucleic acid molecule according to any one of claims 4-6, characterized in that it is used as a primer for a nucleic acid amplification reaction, or as a probe for a hybridization reaction, or for manufacturing a gene chip Or microarray.
17、 如权利要求 1-6及 11中的任一权利要求所述的多肽、 多核苷酸或化合物 的应用, 其特征在于用所述多肽、 多核苷酸或其模拟物、 激动剂、 拮抗剂或抑制 剂以安全有效剂量与药学上可接受的载体组成作为诊断或治疗与肝素结合蛋白 10 异常相关的疾病的药物组合物。  17. Use of a polypeptide, polynucleotide or compound according to any one of claims 1-6 and 11, characterized in that said polypeptide, polynucleotide or mimetic, agonist, antagonist is used Or the inhibitor is composed of a safe and effective dose with a pharmaceutically acceptable carrier as a pharmaceutical composition for diagnosing or treating a disease associated with an abnormality of heparin binding protein 10.
18、 权利要求 1-6及 11中的任一权利要求所述的多肽、 多核苷酸或化合物的 应用, 其特征在于用所述多肽、 多核苷酸或化合物制备用于治疗如恶性肿瘤, 血 液病, HIV感染和免疫性疾病和各类炎症的药物。  18. The use of a polypeptide, polynucleotide or compound according to any one of claims 1-6 and 11, characterized in that the polypeptide, polynucleotide or compound is used for preparing for treating malignant tumors, blood, etc. Disease, HIV infection and immune diseases and drugs of various inflammations.
PCT/CN2000/000704 1999-12-27 2000-12-25 A new polypeptide-heparin bind protein 10 and the polynucleotide encoding it WO2001048004A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21459/01A AU2145901A (en) 1999-12-27 2000-12-25 A new polypeptide-heparin bind protein 10 and the polynucleotide encoding it

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN99125384.1 1999-12-27
CN99125384A CN1301722A (en) 1999-12-27 1999-12-27 New polypeptide-heparin binding protein 10 and polynucleotide coding such polypeptide

Publications (1)

Publication Number Publication Date
WO2001048004A1 true WO2001048004A1 (en) 2001-07-05

Family

ID=5283911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2000/000704 WO2001048004A1 (en) 1999-12-27 2000-12-25 A new polypeptide-heparin bind protein 10 and the polynucleotide encoding it

Country Status (3)

Country Link
CN (1) CN1301722A (en)
AU (1) AU2145901A (en)
WO (1) WO2001048004A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201102108D0 (en) * 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040787A1 (en) * 1995-06-07 1996-12-19 The University Of Arizona Monoclonal antibody detection of proteins on sperm related to fertility

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040787A1 (en) * 1995-06-07 1996-12-19 The University Of Arizona Monoclonal antibody detection of proteins on sperm related to fertility

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOFTUS B.J. ET AL.: "Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q", GENOMICS, vol. 60, no. 3, 1999, pages 295 - 308 *
SULSTON J.E. AND WATERSTON R.: "Toward a complete human genome sequence", GENOME RES., vol. 8, no. 11, 1998, pages 1097 - 1108 *

Also Published As

Publication number Publication date
CN1301722A (en) 2001-07-04
AU2145901A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
WO2001055189A1 (en) A NOVEL POLYPEPTIDE, SECp43, 32 THAT ASSOCIATES SPECIFICALLY WITH HUMAN SELECNOCYSTEINE tRNA AND THE POLYNUCLEOTIDE ENCODING THEREOF
WO2001048004A1 (en) A new polypeptide-heparin bind protein 10 and the polynucleotide encoding it
WO2001081594A1 (en) A novel polypeptide, a human pax protein 17 and the polynucleotide encoding the polypeptide
WO2001075101A1 (en) A novel polypeptide- human transcription regulator 8 and the polynucleotide encoding said polypeptide
WO2001087949A1 (en) A novel polypeptide- human pax protein 9 and the polynucleotide encoding said polypeptide
WO2001072796A1 (en) A novel polypeptide, a human cell differentiation transcription factor 11 and the polynucleotide encoding the polypeptide
WO2001070965A1 (en) A novel polypeptide, a human regulatory transcription factor 15 and the polynucleotide encoding the polypeptide
WO2001072793A1 (en) A novel polypeptide-human proteolytic enzyme regulatory protein 12 and the polynucleotide encoding said polypeptide
WO2001090177A1 (en) A novel polypeptide, a human natural killer cell enhancing factor b13.64 and the polynucleotide encoding the polypeptide
WO2001079432A2 (en) A novel polypeptide, a human cell differentiation transcription factor 58 and the polynucleotide encoding the polypeptide
WO2001081420A1 (en) A novel polypeptide, a laminin 19 and the polynucleotide encoding the polypeptide
WO2001075048A2 (en) A novel polypeptide, human ribosomal protein s11 23 and the polynucleotide encoding the polypeptide
WO2001081399A1 (en) A novel polypeptide, a human pax protein 14 and the polynucleotide encoding the polypeptide
WO2001087951A1 (en) A novel polypeptide -homo helicase 11 and polynucleotide encoding said polypeptide
WO2001090171A1 (en) A novel polypeptide-human robosomal sii protein 12 and the polynucleotide encoding said polypeptide
WO2001074895A1 (en) A novel polypeptide-human cell differentiational transcription factor 12.1 and a polynucleotide sequence encoding the same
WO2001074893A1 (en) A novel polypeptide - human regulatory transcription factor 11.8 and a polynucleotide sequence encoding the same
WO2001087962A1 (en) A new polypeptide-human pax protein 11 and the polynucleotide encoding it
WO2001047998A1 (en) A novel polypeptide - ras gtpase-activating protein 12 and a polynucleotide encoding the same
WO2001083742A1 (en) A novel polypeptide, a human pax protein 11.7 and the polynucleotide encoding the polypeptide
WO2001074998A2 (en) Novel polypeptide - a human protein hydrolytic enzyme regulatory protein 10 and polynucleotide encoding it
WO2001081398A1 (en) A novel polypeptide, a human pax protein 16 and the polynucleotide encoding the polypeptide
WO2001072806A1 (en) A novel polypeptide - human cell differentiational transcription factor 8 and a polynucleotide sequence encoding the same
WO2001047985A1 (en) A novel protein kinase c-13 and encoding sequences thereof
WO2001083544A1 (en) A novel polypeptide, a human pax protein 18 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP